US Pat. No. 10,166,178

DEPILATORY WAX COMPOSITION, METHOD FOR OBTAINING SAME AND USE THEREOF

GRUPO DRV PHYTOLAB, S.L.,...

1. A depilatory composition consisting of:60% to 70% by weight with respect to the total weight of the composition of synthetic resins selected from the group consisting of petroleum resin and colophony resin;
1% to 15% by weight with respect to the total weight of the composition of a carrier;
0.01% to 15% by weight with respect to the total weight of the composition of a hydrophilic cosmetic active agent,
wherein the carrier introduces the active agent into the depilatory composition, and wherein the carrier is obtained by reaction of liquid jojoba wax, mimosa wax and sunflower wax with polyglycerol-3 esters.
US Pat. No. 10,167,459

MODIFIED BETA-FRUCTOFURANOSIDASE FOR FRUCTOOLIGOSACCHARIDE PRODUCTION

STELLENBOSCH UNIVERSITY, ...

1. A modified polypeptide having fructofuranosidase activity, wherein the modified polypeptide comprises an amino acid sequence which is at least 90% identical to SEQ ID NO: 3 and which has at least one amino acid substitution including substitution of the alanine (A) at amino acid position 159 of SEQ ID NO: 3.
US Pat. No. 10,167,203

PREPARATION OF SUSPENSIONS

THE UNIVERSITY OF QUEENSL...

1. A method for preparing a suspension of LDH particles comprising the steps of:a) preparing LDH precipitates by coprecipitation to form a mixture of LDH precipitates and solution, wherein the LDH precipitates and the solution formed in step (a) are left in contact with each other for a period not exceeding 30 minutes;
b) separating the LDH precipitates from the solution;
c) washing the LDH precipitates to remove residual ions;
d) mixing the LDH precipitates with water; and
e) subjecting the mixture of LDH particles and water from step (d) to a hydrothermal treatment step by heating to a temperature of from greater than 80° C. to 150° C. for a period of about 1 hour to about 144 hours to form a dispersed suspension of non-aggregated LDH particles in water, wherein said LDH particles in suspension comprise platelets having a maximum particle dimension of up to 400 nm.
US Pat. No. 10,167,460

VARIANT ENZYMES

DANISCO US INC, , CA (US)...

1. A variant of a parent glycosyl hydrolase 61 (GH61) enzyme, wherein said variant has cellulase augmenting activity, and has at least 90% sequence identity to SEQ ID NO:3, wherein said variant comprises at least one amino acid substitution that is at position I4, wherein the position of each amino acid substitution corresponds to SEQ ID NO:3.
US Pat. No. 10,166,180

TREATMENT OF KERATINIZED TISSUES

1. A method for treating a keratinized tissue condition in a subject in need of treatment thereof, comprising:conducting one or more treatment cycles on the keratinized tissue in the subject in need of treatment thereof, each treatment cycle comprising:
contacting the keratinized tissue with an acid-activated gas-generating composition, the acid-activated gas-generating composition consisting of:
a gas generating agent; and
one or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, a sugar, or sea trace elements;
contacting the keratinized tissue with an acid composition, the acid composition consisting of:
an acid; and
one or more of: water, aloe vera extract, panthenol, a sugar, a nonionic surfactant, a preservative, a water soluble alkali metal halide salt, a water soluble alkali earth metal salt, an ionic surfactant, a sugar, or sea trace elements; and
allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue,
the one or more treatment cycles being effective to at least partly ameliorate the keratinized tissue condition in the subject, the keratinized tissue condition selected from the group consisting of: acneiform eruptions, autoinflammatory syndromes, chronic blistering, conditions of the skin appendages, dermatitis, drug or agent eruptions, infection-related, papulosquamous hyperkeratosis, palmoplantar keratodermas, pruritis, psoriasis, conditions resulting from physical factors, or ionizing radiation-induced conditions.
US Pat. No. 10,167,461

POLYPEPTIDES HAVING CELLULOLYTIC ENHANCING ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME

Novozymes, Inc., Davis, ...

4. A transgenic plant, plant part or plant cell transformed with the nucleic acid construct of claim 1 comprising a polynucleotide encoding the GH61 polypeptide having cellulolytic enhancing activity.
US Pat. No. 10,166,181

SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROGRANULES

1. A pharmaceutical composition of microgranules comprising 22.5 mg triptorelin in the form of triptorelin pamoate, wherein the pharmaceutical composition comprises: a) a first formulation of microgranules comprising approximately 20% (w/w) of triptorelin pamoate mixed with approximately 80% (w/w) PLGA, wherein the PLGA in the first formulation contains approximately 85% lactide and 15% glycolide; and b) a second formulation of microgranules comprising approximately 12% (w/w) triptorelin pamoate mixed with approximately 88% (w/w) poly(D,L lactide-co-glycolide) (PLGA), wherein the PLGA in the second formulation contains approximately 75% lactide and 25% glycolide, wherein the triptorelin is released from the pharmaceutical composition in an immediate amount within hours following injection and then constantly released over a period of at least 168 days.
US Pat. No. 10,166,182

INACTIVATED WHOLE VIRION VACCINE-CONTAINING MICRONEEDLE ARRAY PREPARATION AND METHOD FOR ADMINISTERING THE SAME

FUJIFILM Corporation, To...

1. A microneedle array comprising:a needle portion containing an inactivated whole virion influenza vaccine; and
a sheet portion,
wherein 90% by mass or more of the inactivated whole virion influenza vaccine with respect to the total mass of the vaccine is contained in a region that accounts for not more than 60% of the height of the needle portion from a tip of the needle portion; and
the height of the needle portion is equal to or greater than 50 ?m and equal to or less than 2,000 ?m, and
wherein the needle portion contains a water-soluble polymer, and the water-soluble polymer contains at least hydroxyethyl starch.
US Pat. No. 10,167,463

MODIFIED CHYMOSIN POLYPEPTIDES

DSM IP ASSETS B.V., Heer...

1. A polypeptide having chymosin activity and comprising an amino acid sequence that has at least 90% sequence identity to SEQ ID NO:4, comprises at least one substitution modification relative to SEQ ID NO:4 selected from the group consisting of Q288H, and Q288R, and is capable of hydrolysing bovine alpha s1-casein at position F23F24 so as to form ?s1-I CN (f24-199) more rapidly than the polypeptide of SEQ ID NO:4.
US Pat. No. 10,170,796

LITHIUM SECONDARY BATTERY OF IMPROVED RATE CAPABILITY WITH CATHODE CONTAINING NICKEL MANGANESE COMPLEX OXIDE FOR HIGH-VOLTAGE APPLICATIONS

LG Chem, Ltd., (KR)

1. A lithium secondary battery comprising a cathode, an anode, a separator disposed between the cathode and the anode, and an electrolyte,wherein the electrolyte comprises a mixed solvent of a cyclic carbonate-based material and a propionate-based material, the cathode comprises a lithium manganese composite oxide represented by Formula 1 below as a cathode active material, and the anode comprises a lithium metal oxide represented by Formula 2 below as an anode active material:
LixMyMn2-yO4-zAz  (1)
wherein 0.9?x?1.2, 0 LiaM?bO4-cAc  (2)
wherein M? is at least one element selected from the group consisting of Ti, Sn, Cu, Pb, Sb, Zn, Fe, In, Al, and Zr; 0.1?a?4 and 0.2?b?4 wherein a and b are determined according to oxidation number of M?; 0?c<0.2 wherein c is determined according to oxidation number of A; and A is at least one monovalent or divalent anion,
wherein an amount of the cyclic carbonate-based material is in a range of 1 wt % to 30 wt % based on a total weight of the electrolyte,
wherein a mixing weight ratio of the cyclic carbonate-based material to the propionate-based material is in a range of 5 to 10:90 to 95,
wherein the lithium manganese composite oxide of Formula 1 is a lithium nickel manganese complex oxide (LNMO) represented by Formula 4 below:
LixNiyMn2-yO4  (4)
wherein 0.9?x?1.2 and 0.4?y?0.5, and
wherein the lithium metal oxide of Formula 2 is a lithium titanium oxide (LTO) represented by Formula 5 below:
LiaTibO4  (5)
 wherein 0.5?a?3 and 1?b?2.5.
US Pat. No. 10,167,464

CELL AND BIOFACTOR PRINTABLE BIOPAPERS

The United States of Amer...

1. A method comprising:providing a plurality of structures each comprising:
a porous polymeric film having pores permeated by a first extracellular matrix material; and
a topcoat layer comprising a second extracellular matrix gel disposed on the film;
placing living cells on or within each topcoat layer to form cell-seeded structures; and
stacking the cell-seeded structures to form a stacked structure having alternating layers of polymeric film and topcoat layers;
wherein at least one of the cell-seeded structures has cells positioned in a branched pattern before the cell-seeded structures are stacked.
US Pat. No. 10,167,466

SITE-SPECIFIC NUCLEASE SINGLE-CELL ASSAY TARGETING GENE REGULATORY ELEMENTS TO SILENCE GENE EXPRESSION

CSIR, Pretoria (ZA)

1. A method for silencing gene expression at a single cell level in vitro, the method comprising the steps of:(i) perturbing at least one chromosomal contact in the cell by by inducing a site specific double stranded break in a region of DNA involved in chromosomal contact; (ii) detecting the site of at least one double-stranded break; and (iii) detecting the effect of at least one perturbation on the transcriptional activity of at least one gene of interest, wherein the effect of the perturbation is abrogation of the transcriptional activity of the gene of interest and further wherein the site specific double stranded break in not induced in the gene of interest.
US Pat. No. 10,166,186

NUTRITIONAL AND MEDICINAL ORAL COMPOSITION FOR VETERINARY USE

VIRBAC, Carros (FR)

1. A method for obtaining a nutritional and medicinal oral composition for veterinary use comprising the following steps:a) supplying cores of complete feed extrudate,
b) providing a medicinal agent selected in the group consisting of (i) at least one active principle in the form of non-encapsulated microparticles preconditioned in the form of a solution or a suspension of the active principle in an oily liquid or providing (ii) at least one active principle in the form of non-encapsulated microparticles preconditioned in the form of waxy granules, wherein the active principle is selected from angiotensin-converting enzyme inhibitors (ACE inhibitors), renin inhibitors, angiotensin II receptor antagonists, firocoxib, ciclosporin, S-adenosyl-methionine, eplerenone, spironolactone, amlodipine and levosimendan,
b1) bringing the cores of complete feed extrudate into contact with the medicinal agent, and
b2) coating the extrudate cores obtained at the end of step b1) with at least one layer of fat, at a temperature below 40° C.
US Pat. No. 10,167,467

COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND MIPOMERSEN AND METHODS OF USE THEREOF

AMARIN PHARMACEUTICALS IR...

1. A composition comprising mipomersen and eicosapentaenoic acid, wherein the composition comprises at least about 80%, by weight of all fatty acids (and/or derivatives thereof) present, eicosapentaenoic acid, and no more than about 20%, by weight of all fatty acids (and/or derivatives thereof) present, docosahexaenoic acid or ester thereof.
US Pat. No. 10,166,187

CURCUMIN SOLID LIPID PARTICLES AND METHODS FOR THEIR PREPARATION AND USE

Capsugel Belgium NV, Bor...

1. Solid lipid particles comprising: a lipid hydrophobic matrix; and from about 5 wt. % to about 30 wt. % of curcumin, wherein said lipid hydrophobic matrix comprises5 wt. % to 30 wt. % lecithin;
5 wt. % to 15 wt. % glycerol behenate; andat least 40 wt. % mixture of monoglycerides, diglycerides, and triglycerides having a carbon number ranging from C6 to C40, and wherein said solid lipid particles have an average particle size diameter ranging from 100 ?m to 1500 ?m.
US Pat. No. 10,167,468

METHODS FOR THE TREATMENT OF CARDIOVASCULAR FIBROSIS

UNIVERSITE DE LORRAINE, ...

1. A method for treating cardiovascular fibrosis induced by aldosterone in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity, wherein the inhibitor of NGAL activity is an anti-NGAL antibody.
US Pat. No. 10,167,469

CANCER TREATMENT AND IMMUNE SYSTEM REGULATION THROUGH FAT10 PATHWAY INHIBITION

President and Fellows of ...

1. A method of treating melanoma in a subject comprising administering to the subject an inhibitory nucleic acid specific for an mRNA that encodes FAT10.
US Pat. No. 10,166,189

LYOPHILIZED THERAPEUTIC PEPTIBODY FORMULATIONS

AMGEN INC., Thousand Oak...

1. A method for making a lyophilized therapeutic peptibody composition comprising the steps of:a) preparing a solution of a buffer, a bulking agent, a stabilizing agent, and optionally a surfactant;
wherein said buffer is comprised of 10 mM histidine and wherein the pH is about 5.0;
wherein said bulking agent is about 4% w/v mannitol;
wherein said stabilizing agent is about 2% w/v sucrose;
wherein said surfactant is about 0.004% w/v polysorbate-20; and
b) lyophilizing said therapeutic peptibody;
wherein said therapeutic peptibody comprises a structure of the formula
F1-(L1)e-P1-(L2)f-P2
Wherein the therapeutic peptibody is a dimer and wherein:
F1 is an Fc domain;
P1 and P2 each has the amino acid sequence of SEQ ID NO: 459;
L1 and L2 are each independently linkers;
e and f are each independently 0 or 1.
US Pat. No. 10,167,470

ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS

STICHTING KATHOLIEKE UNIV...

1. A method for treating a CEP290-related disease or condition requiring modulating, splicing of CEP290 c.2991+1655A>G, the method comprising administering to a subject in need thereof an exon skipping antisense oligonucleotide that is sufficiently complementary to SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8 to specifically bind to SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8, respectively.
US Pat. No. 10,166,190

STABILIZED TACROLIMUS COMPOSITION

1. A sustained release tablet comprising (i) a dispersion of tacrolimus, (ii) 8-epitacrolimus, and (iii) a metal chelating agent that is an organic acid, wherein the tacrolimus is the sole active ingredient in the tablet and the tablet comprises a sufficient amount of the metal chelating agent such that the tablet comprises less than 0.5% by weight of the 8-epitacrolimus after 12 weeks of storage at 25° C. and 60% relative humidity, based upon 100% total weight of tacrolimus.
US Pat. No. 10,167,471

INHIBITION OF PCSK9 THROUGH RNAI

RXi Pharmaceuticals Corpo...

1. An RNAi construct for inhibiting expression of a PCSK9 gene, comprising a double-stranded RNA (dsRNA) of 25-27 base pairs in length, the dsRNA comprising: (1) a sense strand having a 5?-end and a 3?-end, wherein the sense strand comprises SEQ ID NO: 65, and wherein the sense strand comprises 12-14 and 10-12 consecutive 2?-modified ribose sugars at the 5?-end and the 3?-end nucleotides, respectively, and (2) an antisense strand having a 5?-end and a 3?-end, which hybridizes to the sense strand.
US Pat. No. 10,166,191

SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB

Incyte Corporation, Wilm...

1. A sustained-release dosage form comprising:(1) about 12.2 wt % ruxolitinib phosphate;
(2) about 20 to about 22 wt % hypromellose;
(3) about 22 to about 42.3 wt % microcrystalline cellulose;
(4) about 20 to about 42.3 wt % lactose monohydrate;
(5) about 1 wt % colloidal silicon dioxide;
(6) about 0.5 wt % magnesium stearate; and
(7) about 2 wt % stearic acid;
wherein administration of said dosage form to a human for at least 16 weeks results in a mean decrease in mean hemoglobin of no more than about 15 g/L or a mean decrease in mean base platelet count of no more than about 100×109/L.
US Pat. No. 10,167,472

PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE AN INCREASED RISK OF ENDOMETRIAL CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION

Medical Diagnostic Labora...

1. A method of inhibiting epithelial to mesenchymal transition of an endometrial cell, comprising the steps of:(a) providing an endometrial cell
(b) providing a RNAi targeted against PME-1 gene, said RNAi hybridizes to a target sequence of PME-1 mRNA, wherein said RNAi is at least one RNAi selected from the group consisting of SEQ ID NOs: 2, 3, 5 and 7;
(c) exposing said endometrial cell to said RNAi, thereby decreasing PME-1 mRNA expression level,
wherein said RNAi inhibits said epithelial to mesenchymal transition as evidenced by at least one characteristic selected from the group consisting of reduced E-cadherin expression, reduced vimentin expression and reduced foci formation.
US Pat. No. 10,166,192

SOLUBILIZED COQ-10

1. An encapsulated composition comprising:coenzyme Q-10 or an analog thereof;
a sufficient quantity of d-limonene suitable to solubilize said coenzyme Q-10 and maintain it in solution at ambient temperature;
with the proviso that the composition does not include a carrier and the solubilized coenzyme Q-10 is not in an emulsion, suspension or elixir.
US Pat. No. 10,167,473

SIRNA AND THEIR USE IN METHODS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF THE ORAI1 GENE

SYLENTIS SAU, Madrid (ES...

1. A method of treating an eye condition characterized by increased expression and/or activity of ORAI1 in a subject in need thereof, the method comprising:topically administering to the corneal surface of the eye of the subject an amount of an siRNA molecule that specifically targets the sequence of SEQ ID NO. 1 effective to decrease the expression and/or activity of ORAI1 in cells of the eye and to treat the eye condition, wherein said eye condition is an ocular allergy and/or conjunctivitis.
US Pat. No. 10,166,193

METHOD OF MAKING A SOFT GEL CAPSULE COMPRISING COQ-10 SOLUBILIZED IN A MONOTERPENE

1. A method of making a soft gel capsule comprising coenzyme Q-10, the method comprising:(a) mixing coenzyme Q-10 with a sufficient quantity of a monoterpene suitable to solubilize said coenzyme Q-10, an additional antioxidant, and an acceptable carrier to form a composition; and
(b) encapsulating said composition in a soft gel capsulewherein:the additional antioxidant is a tocopherol; and
the monoterpene is limonene.
US Pat. No. 10,167,474

CELL-SPECIFIC INTERNALIZING RNA APTAMERS AGAINST HUMAN CCR5 AND USES THEREFORE

City of Hope, Duarte, CA...


US Pat. No. 10,166,194

HYDROCORTISONE CONTROLLED RELEASE FORMULATION

Diurnal Limited, Cardiff...

1. A method of treating a condition that would benefit from circadian delivery of hydrocortisone, comprising:orally administering at between approximately 20:00 hours to 24:00 hours a first pharmaceutical composition to a subject having the condition, wherein the first pharmaceutical composition comprises:
a drug core consisting of 20 mg hydrocortisone, a binding agent and a carrier of microcrystalline cellulose particles; and
a layer comprising a delayed release polymer that delays release of hydrocortisone from said core, wherein the layer comprising the delayed release polymer is in contact with said core, wherein said delayed release polymer is a mixture of (i) poly (methacrylic, methyl methyacrylic) in a ratio of 1:1 and (ii) poly (methacrylic, methyl methyacrylic) in a ratio of 1:2, wherein (i) and (ii) are at a ratio of 1:4; and
orally administering at between approximately 06:00 hours to 10:00 hours a second pharmaceutical composition, wherein the second composition comprises:
a drug core consisting of 10 mg hydrocortisone, a binding agent and a carrier of microcrystalline cellulose particles; and
a layer comprising a delayed release polymer that delays release of hydrocortisone from said core, wherein the layer comprising the delayed release polymer is in contact with said core, wherein said delayed release polymer is a mixture of (i) poly (methacrylic, methyl methacrylic) in a ratio of 1:1 and (ii) poly (methacrylic, methyl methacrylic) in a ratio of 1:2, wherein (i) and (ii) are at a ratio of 1:4;
wherein relative bioavailability of the total 30 mg hydrocortisone in the first and second pharmaceutical compositions is increased relative to when compared to relative bioavailability of a delayed-sustained formulation of hydrocortisone, and
wherein administering the first and second pharmaceutical compositions reproduces the normal circadian release of cortisol,
thereby treating a condition that would benefit from circadian delivery of hydrocortisone.
US Pat. No. 10,167,475

APTAMERS FOR PURIFYING AND QUANTIFYING GELSOLIN AND ITS VARIANTS

1. DNA aptamers represented by SEQ ID No. 6 capable of binding a protein gelsolin represented by SEQ ID No. 1 or its variants represented by SEQ ID No. 2 and 3.
US Pat. No. 10,170,808

BATTERY PACK

SAMSUNG SDI CO., LTD., Y...

1. A battery pack, comprising:a plate-shaped cooling plate, the plate-shaped cooling plate including a stopper on a bottom surface thereof at one lengthwise side of the plate-shaped cooling plate;
a plurality of battery modules, the plurality of battery modules being mounted on a planar top surface of the plate-shaped cooling plate such that surfaces of the battery modules are aligned in a coplanar manner and together directly contact the planar top surface of the plate-shaped cooling plate; and
at least one bracket on the one lengthwise side of the plate-shaped cooling plate, wherein one side of the at least one bracket is coupled with the stopper and the bottom surface of the plate-shaped cooling plate by welding,
wherein each battery module of the plurality of battery modules includes a fixing part thereon, and
wherein another side of the at least one bracket is coupled with the fixing part with a fixing member.
US Pat. No. 10,166,196

VEGETARIAN MICROCAPSULES

DSM NUTRITIONAL PRODUCTS ...

1. A microcapsule, comprising: an agglomeration of primary microcapsules and a loading substance, each individual primary microcapsule having a primary shell, wherein the loading substance is encapsulated by the primary shell, wherein the agglomeration is encapsulated by an outer shell, and wherein the primary shell and the outer shell both comprise a complex coacervate of a first protein and a second polymer,wherein the first protein is pea protein or soy protein;and the second polymer is selected from the group consisting of agar, gellan gum, gum arabic, casein, cereal prolamine, pectin, alginate, carrageenan, xanthan gum, canola protein, dilutan gum, locus bean gum, and welan gum; andwherein the primary and outer shells are thermally crosslinked.
US Pat. No. 10,167,477

MICROORGANISMS AND METHODS FOR THE PRODUCTION OF ANILINE

GENOMATICA, INC., San Di...

1. A method for producing aniline comprising:(a) culturing a non-naturally occurring Escherichia coli under conditions and for a sufficient period of time to produce aniline, wherein the non-naturally occurring Escherichia coli comprises an aniline pathway, the aniline pathway comprising an anthranilate synthase, a 3-dehydroquinate synthase, a 3-dehydroquinate dehydratase, a shikimate dehydrogenase or a quinate/shikimate dehydrogenase, a shikimate kinase, a 3-phosphoshikimate-1-carboxyvinyltransferase, a chorismate synthase, and an anthranilate decarboxylase, wherein the non-naturally occurring Escherichia coli comprises at least two exogenous nucleic acids encoding at least two enzymes of the aniline pathway selected from the group consisting of the 3-dehydroquinate synthase, the anthranilate synthase, the 3-dehydroquinate dehydratase, the shikimate dehydrogenase or the quinate/shikimate dehydrogenase, the shikimate kinase, the 3-phosphoshikimate-1-carboxyvinyltransferase, and the chorismate synthase, wherein the anthranilate decarboxylase in the non-naturally occurring Escherichia coli is endogenous, and wherein the aniline pathway enzymes are expressed in a sufficient amount to produce aniline; and
(b) isolating aniline.
US Pat. No. 10,170,297

COMPOSITIONS AND METHODS USING SAME FOR FLOWABLE OXIDE DEPOSITION

VERSUM MATERIALS US, LLC,...

3. A formulation comprising hexyltrimethoxysilane; di-iso-propylaminosilane; an amine; and 3,5-dimethyl-1-hexyn-3-ol.
US Pat. No. 10,166,197

SUGAR ESTER NANOPARTICLE STABILIZERS

1. A method for preparing a solid dosage form containing nanoparticles, the method comprising the steps of:(a) reducing particle size of at least one pharmaceutically active ingredient dispersed in a solution containing a sugar ester nanoparticle stabilizer to form a nanosuspension; and
(b) drying the nanosuspension of step (a) to form the solid dosage form,
wherein the sugar ester nanoparticle stabilizer is a sugar fatty acid ester, and
wherein no excipient other than the sugar ester nanoparticle stabilizer is added for stabilizing the nanoparticles, and wherein the ratio of the total amount of the sugar ester nanoparticle stabilizer to the total amount of the pharmaceutically active ingredient in the solid dosage form is equal to or less than 1:1.
US Pat. No. 10,167,478

REPLICATIVE MINICIRCLE VECTORS WITH IMPROVED EXPRESSION

Nature Technology Corpora...

1. A method of constructing a eukaryotic replicative minicircle expression vector and expressing a gene of interest therefrom comprising:a) combining i) a eukaryotic region with 5? and 3? ends encoding a gene of interest and comprising an intron, the intron comprising a 5? splice donor and a 3? acceptor branch site, a bacterial replication origin selected from the group consisting of R6K replication origin, and ColE2-P9 replication origin, and an RNA selectable marker; with ii) a spacer region linking the 5? and 3? ends of the eukaryotic region, said spacer region being less than 500 basepairs in length, to create a eukaryotic replicative minicircle expression vector; and
b) introducing said replicative minicircle expression vector into a target eukaryotic cell or a eukaryotic organism comprising the target eukaryotic cell, under conditions wherein the target eukaryotic cell is transfected and said gene of interest is expressed.
US Pat. No. 10,166,198

SOLID NANOPARTICLE WITH INORGANIC COATING

Nanexa AB, Uppsala (SE)

1. A method of preparing a controlled or delayed release pharmaceutical composition in a form of a sterile injectable or infusible suspension of particles comprising:i. a plurality of coated particles of a size that is from 0.1 ?m to 50 ?m, said coated particles having a solid core comprising a drug, said solid core being enclosed by one or more metal oxide materials; and
ii. a pharmaceutically and parentally acceptable diluent,the method comprising the sequential steps of:(1) applying an initial coating of at least one metal oxide to said solid cores in an atomic layer deposition reactor;
(2) discharging the coated particles from the reactor and subjecting the coated particles to agitation to disaggregate particle aggregates formed during step (1);
(3) reintroducing the disaggregated, coated particles from step (2) into an atomic layer deposition reactor and applying a further coating of at least one metal oxide to the reintroduced particles;
(4) optionally repeating steps (2) and (3) one or more times to increase a total thickness of the one or more metal oxide materials that enclose said solid core; and
(5) admixing said coated particles obtained from step (3) or step (4) with said pharmaceutically and parenterally acceptable diluent to form said pharmaceutical composition.
US Pat. No. 10,167,222

SELENIUM-FREE SUNGLASS MATERIAL WITH BROWN TINT

Corning Incorporated, Co...

1. A glass comprising B2O3, SiO2, and Fe, said Fe including ferric ion (Fe3+) and ferrous ion (Fe2+), said glass lacking Se and having (i) a tint with a chromaticity coordinate x in the range from 0.37-0.65, and (ii) a concentration of said ferrous ion (Fe2+) sufficient to provide an average percent transmittance (% T) over the wavelength range from 780 nm-2000 nm, for a thickness of 1.9 mm, of less than 3%.
US Pat. No. 10,167,479

AGROBACTERIUM STRAINS FOR PLANT TRANSFORMATION

TEMASEK LIFE SCIENCES LAB...

1. Agrobacterium tumefaciens strain AGL2 deposited with the American Type Culture Collection under Accession Number PTA 10447.
US Pat. No. 10,166,200

BUFFERED OXYGEN THERAPEUTICS

NuvOx Pharma LLC, Tucson...

1. An oxygen therapeutic composition, comprising:water;
a perfluorocarbon material selected from perfluoropentane and perfluorohexane;
a buffer; and
dipalmitoylphosphatidylcholine and/or dipalmitoylphosphatidylcholine mixed with dipalmitoylphosphatidylethanolamine with covalently linked poly(ethylene glycol) (PEG) with molecular mass 5000;wherein:the buffer comprises NaH2PO4 and Na2HPO4 and stabilizes a pH of the composition at between about 6.5 to about 7.5; and
the composition comprises a viscosity of about 2.0 to about 3.5 mPas.
US Pat. No. 10,167,482

GENES AND USES FOR PLANT ENHANCEMENT

Monsanto Technology LLC, ...

1. A plant cell nucleus comprising a stably integrated recombinant DNA construct wherein said recombinant DNA comprises a heterologous promoter that is functional in said plant cell and that is operably linked to a protein coding DNA encoding at least one protein having an amino acid sequence comprising at least 95% amino acid sequence identity to SEQ ID NO:936 and having the function of SEQ ID NO:936and wherein said recombinant DNA construct is stably integrated into a chromosome in a plant cell nucleus which is selected by screening a population of transgenic plants that have said recombinant DNA and an enhanced trait as compared to control plants that do not have said recombinant DNA in their nuclei; and wherein said enhanced trait is selected from group of enhanced traits consisting of increased yield and enhanced nitrogen use efficiency.
US Pat. No. 10,166,202

TREATMENT OF HEPATIC ENCEPHALOPATHY AND LIVER CIRRHOSIS

Yissum Research Developme...

1. A method for reducing oxidative stress in liver tissue of a subject with non-alcoholic steatohepatitis but without fibrosis or cirrhosis, comprising administering a therapeutically effective amount of cannabidiol to the subject.
US Pat. No. 10,167,483

HERBICIDE RESISTANCE GENES

Dow AgroSciences LLC, In...

1. An expression cassette for expression in a plant cell, comprising a polynucleotide operably linked to a heterologous plant promoter or a plant virus promoter, wherein said polynucleotide encodes a protein that catalyzes degradation of phenoxy auxin and pyridyloxy auxin herbicides, wherein the polynucleotide that encodes said protein comprises SEQ ID NO:3.
US Pat. No. 10,167,227

FIBERGLASS MATERIALS, METHODS OF MAKING, AND APPLICATIONS THEREOF

1. A composite glass material comprising:Na2O about 2.1 to about 8.2 weight percent;
SiO2 55 to 70 weight percent;
Al2O3 5 to 11 weight percent;
CaO 15 to 20 weight percent;
MgO 1 to 3 weight percent; and
K2O less than about 0.2 weight percent.
US Pat. No. 10,167,484

COMPOSITIONS AND METHODS FOR CONTROL OF INSECT INFESTATIONS IN PLANTS

Monsanto Technology LLC, ...

1. A method for controlling Western Corn Rootworm infestation on a plant, comprising topically applying to the plant a pesticide composition comprising a dsRNA targeting for suppression an essential gene in the Western Corn Rootworm and providing the plant in the diet of the Western Corn Rootworm, wherein the plant comprises a nucleic acid sequence encoding at least a first Bacillus thuringiensis insecticidal protein for controlling the Western Corn Rootworm.
US Pat. No. 10,167,228

LITHIUM INFUSED RAW FLY ASH FOR THE PRODUCTION OF HIGH STRENGTH CEMENTITIOUS PRODUCTS

VHSC, LTD., Tortola (VG)...

1. A method for producing a cementitious product having a greater than Grade 100 slag performance, the method comprising:mixing raw fly ash with a lithium compound to produce the cementitious product, wherein 17.5% or greater of the raw fly ash includes calcium-containing minerals.
US Pat. No. 10,167,485

PRODUCTION OF VIRAL VECTORS

The Regents of the Univer...

1. A method for producing helper-dependent adenoviral vectors comprising:a) providing:
a helper-dependent adenoviral DNA comprising a first origin of replication, a helper viral DNA comprising a second origin of replication, wherein said first origin of replication and said second origin of replication are not linked to terminal protein or any terminal protein remnant,
a vector comprising a nucleic acid encoding an adenoviral protein IX operably linked to a heterologous promoter, and
target cells; and
b) transfecting said target cells with said helper-dependent adenoviral DNA, said helper viral DNA, and said vector comprising a nucleic acid encoding an adenoviral protein IX operably linked to a heterologous promoter under conditions such that helper-dependent adenoviral vectors are produced.
US Pat. No. 10,167,229

QUICK-DRYING BUILDING MATERIAL COMPOSITION BASED ON A MINERAL HYBRID BINDER

SIKA TECHNOLOGY AG, Baar...

1. A gypsum composition comprising20 to 70 wt % of a mixture of calcium aluminate and calcium sulfate hemihydrate and/or anhydrite and/or calcium sulfate dihydrate as hydraulic binders, where the weight ratio of calcium aluminate to calcium sulfate hemihydrate and/or anhydrite and/or calcium sulfate dihydrate binder is in the range from 1:1 to 1:3.5, and
30 to 80 wt % of fillers,
the weight figures being based in each case on the dry weight of the gypsum composition, wherein
at least 80 wt % of the total amount of calcium sulfate hemihydrate, and anhydrite and dihydrate is accounted for by the calcium sulfate hemihydrate, and
the gypsum composition is composed of up to about 3 wt % cement binders.
US Pat. No. 10,167,486

VECTORS AND METHODS FOR LONG-TERM IMMUNE EVASION TO PROLONG TRANSPLANT VIABILITY

NATIONAL INSTITUTE OF TRA...

1. A kit for altering allogeneic human cells for a human recipient, the kit comprising:a set of lentivirus vectors wherein each of the lentivirus vectors expresses a sequence targeting a consensus conserved nucleic acid sequence, which when expressed in cells, functions as a negative modulator for nucleic acid encoding a domain having a mismatch in an HLA protein and wherein the set of lentivirus vectors comprises individual lentivirus vectors that correspond to individual HLA mismatches for a set of HLA mismatches that consist of HLA Class I mismatches and at least one HLA Class II mismatch;
wherein the kit is for treatment of human cells by an appropriate subset of the set of lentivirus vectors based at least in part on a determined subset of the set of HLA mismatches between a human donor and a human recipient or between human cells and a human recipient.
US Pat. No. 10,166,206

TOPICAL COMPOSITIONS AND METHODS FOR MAKING AND USING SAME

SEBELA INTERNATIONAL BERM...

1. A gel composition for topical administration comprising:(i) naftifine or a pharmaceutically acceptable salt thereof, present in an amount of from about 0.5 wt % to about 4 wt %;
(ii) a solvent comprising a glycol solvent component and an alkyl alcohol solvent component, present in an amount of from about 10 wt % to about 50 wt %;
(iii) a hydroxy cellulose, present in an amount of from about 0.75 wt % to about 2.25 wt %;
(iv) a polysorbate solubilizing agent present in an amount of from about 3 wt % to about 8 wt %;
(v) an amine pH adjuster in an amount of from about 0.12 wt % to about 0.23 wt %; and
one or more of: water, a preservative, a chelating agent, a coloring agent, and a fragrance, wherein the gel composition exhibits an in vitro release rate under the SUPAC-SS guidance of from about 2700 ?g/cm2/hr1/2 to about 3134 ?g/cm2/hr1/2.
US Pat. No. 10,167,230

ULTRA STABLE TILE BACKER BOARD FORMULATION

1. A tile backer board comprising the product of:a. forming a cementitious material that is the product of:
(i) blending
a) 29 wt. % to 40 wt. %, based on the final total weight of the cementitious material, of a magnesium oxide dry powder containing 80 wt. % to 98 wt. % of magnesium oxide, the magnesium oxide powder having a surface area of from 5 m2/g to 50 m2/g and an average particle size of from about 0.3 ?m to about 90 ?m, and wherein more than about 90 wt. % of the particles of the magnesium oxide powder have a particle size of less than or equal to about 40 ?m, with
b) 14 wt. % to 18 wt. %, based on the final total weight of the cementitious material, of an aqueous solution of magnesium chloride, the aqueous solution of magnesium chloride comprising 20 wt. % to 30 wt. % of magnesium chloride,
and reacting the magnesium oxide and the magnesium chloride to form a liquid suspension;
(ii) mixing the liquid suspension for from 2 minutes to 10 minutes;
(iii) adding 0.1 wt. % to 10 wt. %, based on the final total weight of the cementitious material, of a stabilizing material to the mixed liquid suspension, wherein the stabilizing material is:
1) an aqueous solution comprising 55 wt. % to 65 wt. % of phosphorous acid (H3PO3); or
2) an aqueous solution comprising 80 wt. % to 90 wt. % of phosphoric acid (H3PO4); and
(iv) allowing the liquid suspension with the stabilizing material to react for from 1 minute to 4 minutes to form an amorphous phase cementitious material;
b. blending 35 wt. % to 79.9 wt. %, based on the final total weight of the tile backer board, of the formed amorphous phase cementitious material with 0.1 wt. % to 30 wt. %, based on the final total weight of the tile backer board, of an aggregate comprising particles having a diameter from 1 nm to 10 nm, wherein the aggregate comprises at least one selected from the group consisting of wood, perlite, styrene-based foam beads, calcium carbonate powder, and glass particulates, thereby forming a concrete; and
c. pouring the formed concrete over 0.1 wt. % to 2 wt. %, based on the final total weight of the tile backer board, of a reinforcing material that cures into the tile backer board, the reinforcing material comprising a non-woven or woven silica-containing mat or a non-woven or woven hydrocarbon-containing mat;
wherein a portion of the amorphous phase cementitious material grows a plurality of crystals, each crystal having a molecular weight of from 280 to 709 and being encapsulated by the amorphous phase cementitious material;
wherein a majority of the stabilizing material is consumed during curing into a nano-molecular veneer over the crystals while increasing the surface area of the plurality of crystals by 2% to 49%; and
wherein the nano-molecular veneer is insoluble in water and protects the plurality of crystals from degradation in water at temperatures of from 20° C. to 60° C. for from 24 hours to 56 days.
US Pat. No. 10,167,231

PROCESS FOR MAKING ULTRA STABLE TILE BACKER BOARD

1. A process of making a tile backer board comprising:a. forming a cementitious material, comprising:
(i) blending
a) 29 wt. % to 40 wt. %, based on the final total weight of the cementitious material, of a magnesium oxide dry powder containing 80 wt. % to 98 wt. % of magnesium oxide, the magnesium oxide powder having a surface area of from 5 m2/g to 50 m2/g and an average particle size of from about 0.3 ?m to about 90 ?m, and wherein more than about 90 wt. % of the particles of the magnesium oxide powder have a particle size of less than or equal to about 40 ?m, with
b) 14 wt. % to 18 wt. %, based on the final total weight of the cementitious material, of an aqueous solution of magnesium chloride, the aqueous solution of magnesium chloride comprising 20 wt. % to 30 wt. % of magnesium chloride,
and reacting the magnesium oxide and the magnesium chloride to form a liquid suspension;
(ii) mixing the liquid suspension for from 2 minutes to 10 minutes;
(iii) adding 0.1 wt. % to 10 wt. %, based on the final total weight of the cementitious material, of a stabilizing material to the mixed liquid suspension, wherein the stabilizing material is:
1) an aqueous solution comprising 55 wt. % to 65 wt. % of phosphorous acid (H3PO3); or
2) an aqueous solution comprising 80 wt. % to 90 wt. % of phosphoric acid (H3PO4);
(iv) allowing the liquid suspension with the stabilizing material to react for from 1 minute to 4 minutes to form an amorphous phase cementitious material;
b. blending 35 wt. % to 79.9 wt. %, based on the final total weight of the tile backer board, of the formed amorphous phase cementitious material with 0.1 wt. % to 30 wt. %, based on the final total weight of the tile backer board, of an aggregate comprising particles having a diameter from 1 nm to 10 nm, wherein the aggregate comprises at least one selected from the group consisting of wood, perlite, styrene-based foam beads, calcium carbonate powder, and glass particulates, thereby forming a concrete; and
c. pouring the formed concrete over 0.1 wt. % to 2 wt. %, based on the final total weight of the tile backer board, of a reinforcing material that cures into the tile backer board, the reinforcing material comprising a non-woven or woven silica-containing mat or a non-woven or woven hydrocarbon-containing mat;
wherein a portion of the amorphous phase cementitious material grows a plurality of crystals, each crystal having a molecular weight of from 280 to 709 and being encapsulated by the amorphous phase cementitious material;
wherein a majority of the stabilizing material is consumed during curing into a nano-molecular veneer over the crystals while increasing the surface area of the plurality of crystals by 2% to 49%; and
wherein the nano-molecular veneer is insoluble in water and protects the plurality of crystals from degradation in water at temperatures of from 20° C. to 60° C. for from 24 hours to 56 days.
US Pat. No. 10,167,488

HETEROLOGOUS PATHWAY TO PRODUCE TERPENES

The Regents of the Univer...

1. A cell genetically engineered to express a heterologous metabolic pathway comprising heterologous Bombyx mori and/or Choristoneura fumiferana mevalonate pathway enzymes, wherein the cell produces a product of the metabolic pathway that is a C16 terpene, wherein the mevalonate pathway enzymes comprise ?-hydroxy ?-methylglutaryl-CoA synthase (HMGS), ?-hydroxy ?-methylglutaryl-CoA reductase (HMGR), mevalonate kinase (MevK), mevalonate phosphate kinase (MevPK), mevalonate pyrophosphate decarboxylase (MevPPD), isopentenyl pyrophosphate isomerase (IPPI) and farnesyl pyrophosphate synthase (FPPS), wherein the metabolic pathway further comprises a terpene cyclase.
US Pat. No. 10,166,208

ORAL CARE COMPOSITION

Next Science IP Holdings ...

1. An oral care composition useful for treating a microbe-induced condition of the oral cavity of a subject in need thereof, said oral care composition consisting of (1) an oral rinse containing eucalyptol, thymol, menthol, and methyl salicylate in an alcohol vehicle, (2) an aqueous composition consisting of dissociation products of at least one base and a phosphate or sulfate in water, and (3) from 0.5 to 1.8 g/L of at least one cationic surfactant, said oral care composition having a pH of from 7.5 to 10 and an osmolarity of from 1.25 to 2.5 Osm/L.
US Pat. No. 10,167,232

PROCESS FOR MAKING AN ULTRA STABLE CEMENTITIOUS CONSTRUCTION MATERIAL

1. A process of making a cementitious material comprising:(i) blending
a) 29 wt. % to 40 wt. %, based on the final total weight of the cementitious material, of a magnesium oxide dry powder containing 80 wt. % to 98 wt. % of magnesium oxide, the magnesium oxide powder having a surface area of from 5 m2/g to 50 m2/g and an average particle size of from about 0.3 ?m to about 90 ?m, and wherein more than about 90 wt. % of the particles of the magnesium oxide powder have a particle size of less than or equal to about 40 ?m, with
b) 14 wt. % to 18 wt. %, based on the final total weight of the cementitious material, of an aqueous solution of magnesium chloride, the aqueous solution of magnesium chloride comprising 20 wt. % to 30 wt. % of magnesium chloride,
 and reacting the magnesium oxide and the magnesium chloride to form a liquid suspension;
(ii) mixing the liquid suspension for from 2 minutes to 10 minutes;
(iii) adding 0.1 wt. % to 10 wt. %, based on the final total weight of the cementitious material, of a stabilizing material to the mixed liquid suspension, wherein the stabilizing material is:
1) an aqueous solution comprising 55 wt. % to 65 wt. % of phosphorous acid (H3PO3); or
2) an aqueous solution comprising 80 wt. % to 90 wt. % of phosphoric acid (H3PO4);
(iv) allowing the liquid suspension with the stabilizing material to react for from 1 minute to 4 minutes to form an amorphous phase cementitious material;wherein a portion of the amorphous phase cementitious material grows a plurality of crystals, each crystal having a molecular weight of from 280 to 709 and being encapsulated by the amorphous phase cementitious material;wherein a majority of the stabilizing material is consumed during curing into a nano-molecular veneer over the crystals while increasing the surface area of the plurality of crystals by 2% to 49%; andwherein the nano-molecular veneer is insoluble in water and protects the plurality of crystals from degradation in water at temperatures of from 20° C. to 60° C. for from 24 hours to 56 days.
US Pat. No. 10,167,489

MICROBIAL OILS WITH LOWERED POUR POINTS, DIELECTRIC FLUIDS PRODUCED THEREFROM, AND RELATED METHODS

Corbion Biotech, Inc., S...

1. A method of producing a microalgal oil, the method comprising:a. cultivating a genetically engineered Chlorella or Prototheca cell engineered to ablate or downregulate expression of an endogenous fatty acyl-ACP thioesterase gene until the microbe has at least 10% oil by dry weight;
b. separating the oil from the microbe; and optionally
c. subjecting the oil to refining, bleaching, deodorizing or degumming to produce RBD microbial oil.
US Pat. No. 10,169,541

METHOD AND SYSTEMS FOR CHARACTERIZING SKIN RELATED CONDITIONS

uBiome, Inc., San Franci...

1. A system for evaluating a skin-related condition in relation to a user, the system comprising:a handling network operable to collect containers comprising material from a set of users, the handling network comprising:
a library preparation system operable to fragment and perform multiplex amplification on the material using a primer compatible with a genetic target associated with the skin-related condition;
a sequencing system operable to determine microorganism sequences from sequencing the material;
a microbiome characterization system operable to:
determine microbiome composition data and microbiome functional diversity data based on an alignment between the microorganism sequences and reference sequences associated with the skin-related condition,
collect supplementary data associated with the skin-related condition for the set of users, and
transform the supplementary data and features extracted from the microbiome composition data and the microbiome functional diversity data into a characterization model for the skin-related condition; and
a treatment system operable to provide a treatment to the user for the skin-related condition based on characterizing the user with the characterization model in relation to the skin-related condition.
US Pat. No. 10,166,209

METHODS OF REDUCING APOLIPOPROTEIN C-III

Amarin Pharmaceuticals Ir...

1. A method of reducing an apolipoprotein C-III (“APOC3”) level of a subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to about 499 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of at least about 95%, by weight of all fatty acids present, ethyl eicosapentaenoate per day, wherein the APOC3 level is reduced by at least about 15%.
US Pat. No. 10,167,233

PRODUCT HAVING A HIGH ALUMINA CONTENT

1. A sintered refractory product having the shape of a block and consisting of:grains having a size of greater than 100 ?m, referred to as “coarse grains”, the coarse grains forming an aggregate, and
a matrix bonding said coarse grains and consisting of grains having a size of less than or equal to 100 ?m,the aggregate representing between 45% and 90% by weight of the product,said product having a composition such that, as a weight percentage on the basis of the oxides:Al2O3>80%,
SiO2<15%,
Na2O<0.15%
Fe2O3<0.05%,
CaO<0.1%,
the other oxides constituting the balance to 100%,the content of Na2O in the matrix being greater than 0.010%, as a weight percentage on the basis of the weight of the product, the product having crystalline phases.
US Pat. No. 10,167,490

ERGOTHIONEINE PRODUCTION THROUGH METABOLIC ENGINEERING

Ergo Health LLC, Newton,...

1. A process for preparing ergothioneine, the process comprising:(i) incubating histidine or hercynine with a reaction mixture comprising recombinantly expressed:
(a) EgtA protein,
(b) EgtB protein,
(c) EgtC protein,
(d) EgtD protein, and
(e) EgtE protein, wherein the EgtE protein is produced from recombinant coexpression with a gene encoding a FAD synthetase to facilitate EgtE production; and
(ii) isolating ergothioneine from the reaction mixture.
US Pat. No. 10,169,542

SYSTEMS AND METHODS FOR AUTOMATICALLY DETERMINING MYOCARDIAL BRIDGING AND PATIENT IMPACT

HeartFlow, Inc., Redwood...

1. A computer-implemented method for determining risks of myocardial bridging in a patient, the method comprising:receiving a plurality of patient-specific multiphase images;
generating, based on the plurality of multiphase images, a patient-specific mesh model of the patient's heart;
computing cross-sectional areas for one or more segments of the patient-specific mesh model;
computing, from the computed cross-sectional areas of the patient-specific mesh model, systolic compression of at least one selected segment of the segments of the patient-specific mesh model;
computing, at the at least one selected segment, a value of a hemodynamic characteristic using a computational fluid dynamics or structural mechanics analysis; and
outputting a coronary risk assessment for the patient or outputting a hemodynamic significance of the systolic compression in the patient-specific mesh model, based on the computed value of the hemodynamic characteristic.
US Pat. No. 10,166,210

METHODS OF SUBTYPING CRC AND THEIR ASSOCIATION WITH TREATMENT OF COLON CANCER PATIENTS WITH OXALIPLATIN

NSABP Foundation, Inc., ...

1. A method of treating stage III colon cancer patients comprising:a) obtaining a colon cancer tumor tissue sample from a patient with stage III colon cancer,
b) contacting a genetic sample from said colon cancer tumor tissue sample with a plurality of specific genetic sequence binding targets and measuring the expression level of a panel of 72 genes, wherein the 72 genes are AKAP12, ANKRD44, BGN, BHLHE41, BMP7 C8orf84, CAB39L, CDKN2B, CKMT2, COL11A1, COMP, CPE, CSGALNACT1, CXCL10, CXCL11, CXCL13, CXCL2, CXCL9, CYP1B1, DAPK1, DCBLD2, DPEP1, EPB41L4B, ERAP2, F5, FAP, FGL2, FN1, FNDC1, GBP1, GBP4, GPX3, GRM8, GZMB, HGD, HOXA13, HSD17B2, ID4, IDO1, IL8, INHBA, MFAP5, MGP, MMP11, MMP28, NFIB, OAS2, PAPPA, PIGR, PLA2G12B, POU2AF1, PRAP1, PROM2, PSMB9, PTPRC, ROBO1, SDC2, SELL, SERPINE1, SFRP2, SGK2, SLC4A4, SPARC, SPP1, SSPN, STC1, TACSTD2, TGFBR3, TM4SF1, TYMS, VCAN, and VNN1,
c) obtaining a gene expression signature for said colon cancer tumor tissue from the gene expression level of the panel of 72 genes in b),
d) identifying said colon cancer tumor tissue as being a subtype responsive to oxaliplatin, and
e) administering oxaliplatin in combination with 5?fluorouracil and leucovorin (FULV) to said patient with Stage III colon cancer in a).
US Pat. No. 10,167,491

METHODS FOR DEGRADING OR CONVERTING CELLULOSIC MATERIAL

1. An enzyme composition for degrading or converting a cellulosic material to fermentable sugars comprising one or more enzymes having cellulolytic and/or hemicellulolytic activity and a polypeptide having catalase activity, wherein the presence of the polypeptide having catalase activity increases the production of fermentable sugars, as compared to a degradation or conversion of a cellulosic material not in the presence of a polypeptide having catalase activity, wherein the polypeptide having catalase activity is selected from the group consisting of:(a) a polypeptide having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 2, the sequence of amino acids 20 to 733 of SEQ ID NO: 4, or the sequence of amino acids 20 to 765 of SEQ ID NO: 6;
(b) a polypeptide encoded by a polynucleotide that hybridizes under high stringency conditions with (i) the sequence of SEQ ID NO: 1, the nucleic acid sequence of nucleotides 58 to 2418 of SEQ ID NO: 3, or the nucleic acid sequence of nucleotides 58 to 3040 of SEQ ID NO: 5, (ii) the cDNA sequence thereof, or (iii) the full-length complement of (i) or (ii);
(c) a polypeptide encoded by a polynucleotide having at least 70% sequence identity to the sequence of SEQ ID NO: 1, the nucleic acid sequence of nucleotides 58 to 2418 of SEQ ID NO: 3, the nucleic acid sequence of nucleotides 58 to 3040 of SEQ ID NO: 5, or the cDNA sequence thereof; and
(d) a fragment of the polypeptide of (a), (b), or (c) that has catalase activity.
US Pat. No. 10,167,492

PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN

AMGEN INC., Thousand Oak...

1. A method for manipulating the fucosylated glycan content on a recombinant protein comprising inoculating a bioreactor with mammalian host cells expressing the recombinant protein, culturing the mammalian host cells in a serum free, chemically defined cell culture medium; wherein the cell culture medium includes from 10 to 100 ppb copper and from 50 to 1000 nM manganese, at pH 7.0, harvesting the recombinant protein produced by the host cell, wherein the level of afucosylated glycans on the recombinant protein increases compared to the afucosylated glycan level obtained in the same cell culture medium at a lower pH.
US Pat. No. 10,167,493

METHODS FOR PRODUCING CAROTENOIDS FROM FERMENTATION BY-PRODUCTS

DIREVO Industrial Biotech...

1. A method for extracting a carotenoid for use in animal feed, wherein said method comprises the steps of:a) converting starch containing material to fermentable sugars;
b) fermenting said fermentable sugars with a microorganism;
c) separating a by-product from said fermentation;
d) recovering oil from said by-product;
e) contacting said oil with a solid adsorption material;
f) separating said solid adsorption material from said oil;
g) extracting a carotenoid from said adsorption material using tert butyl methyl ether; and
h) introducing said extracted carotenoid as an ingredient into animal feed.
US Pat. No. 10,167,496

SUMOYLATION ASSAY AND RELATED REAGENTS

The UAB Research Foundati...

1. A method of identifying an inhibitor of sumoylation comprising:(a) contacting a candidate agent with (i) a small ubiquitin-like modifier (SUMO)-conjugating peptide comprising an N-terminal linker and a detectable tag, and (ii) a SUMO comprising a metal chelate or a metal cryptate, under conditions that allow binding between the SUMO-conjugating peptide and the SUMO; and
(b) detecting the detectable tag thereby determining the level of binding between the SUMO-conjugating peptide and SUMO;
a reduced level of binding as compared to the level of binding in the absence of the candidate agent indicating the agent inhibits sumoylation.
US Pat. No. 10,166,219

FORMULATIONS AND METHODS OF MANUFACTURING FORMULATIONS FOR USE IN COLONIC EVACUATION

Redhill Bipharma Ltd., T...

1. A coated tablet, comprising: an intra-granular fraction combined with an extra-granular fraction, and a coating layer,wherein the intra-granular fraction includes granules comprising micronized sodium picosulfate, microcrystalline cellulose, magnesium oxide, and crospovidone, and wherein the intra-granular fractions excludes sodium starch glycolate,
wherein the extra-granular fraction includes one or more organic acids, microcrystalline cellulose, and crospovidone, and wherein the extra-granular fraction excludes sodium starch glycolate and magnesium stearate,
wherein the organic acid is one of ascorbic acid, citric acid, tartaric acid, or combinations thereof, and
wherein the coating layer delays dissolution beyond the mouth of a patient.
US Pat. No. 10,167,501

METHODS AND APPARATUS FOR QUANTIFICATION OF NUCLEIC ACID AMPLIFICATION BY MONITORING IMPEDANCES

AUCKLAND UNISERVICES LIMI...

1. A method for amplifying a target nucleic acid, the method comprising the steps ofa) providing a reaction volume comprising
(i) a first electrode comprising an electrochemically-active conducting polymer,
(ii) a first single-stranded nucleic acid molecule capable of hydridizing to a first portion of a target nucleic acid sequence, wherein the first nucleic acid molecule is covalently attached to the electrochemically-active conducting polymer, and
(iii) a second electrode;
b) providing a reaction mixture to the reaction volume, the reaction mixture comprising
(i) the target nucleic acid,
(ii) a second single-stranded nucleic acid molecule comprising nucleic acid sequence complementary to a second portion of the target nucleic acid sequence,
(iii) a nucleic acid polymerase,
(iv) ferro-ferricyanide, and
(v) a supply of reagents for a nucleic acid amplification reaction;
c) performing a polymerase chain reaction, and
d) measuring the impedance of the first electrode at least once during the polymerase chain reaction.
US Pat. No. 10,167,503

MUTANT PORES

Oxford Nanopore Technolog...

1. A mutant Mycobacterium smegmatis porin (Msp) monomer comprising a variant of the sequence that is at least 90% identical to the sequence of SEQ ID NO: 2, which comprises a cap forming region and a barrel forming region, wherein the variant:(a) does not comprise aspartic add (D) at position 90;
(b) does not comprise aspartic acid (D) at position 91;
(c) comprises aspartic add (D) or glutamic add (E) at position 93; and
(d) comprises one or more amino acid modifications in the cap forming region and/or the barrel forming region of SEQ ID NO: 2 such that, when the mutant Msp monomer forms a pore, the net negative charge of inward facing amino acids is decreased, and wherein the cap forming region comprises amino acids 1 to 72 and 122 to 184 of SEQ ID NO: 2.
US Pat. No. 10,168,271

MICROPARTICLES HAVING REFERENCE MARKERS ARRANGED IN DIFFERENT CONCENTRATIONS

The General Hospital Corp...

1. A method of sorting a plurality of cells, the method comprising:arranging a plurality of microparticles into an array on a substrate in a microfluidic device, wherein each microparticle of the plurality of microparticles comprises a plurality of reference markers embedded within the microparticle or attached to a surface of the microparticle
wherein the plurality of reference markers are arranged in two or more regions, each region having a different overall concentration of the reference markers,
wherein the plurality of reference markers comprise chemokines, and wherein the plurality of reference markers arranged in the two or more regions establish a chemokine concentration gradient within the microparticle or along the surface of the microparticle, and
wherein the microparticle is tubular and has an opening that extends through the microparticle;
introducing a plurality of cells to the array of microparticles under conditions that enable at least some of the cells to adhere to the microparticles;
removing the plurality of microparticles, to which the cells are adhered, from the substrate;
transferring the plurality of microparticles, to which the cells are adhered, to a detection region; and
detecting, for each of two or more microparticles that pass through the detection region, a microparticle feature; and
sorting the two or more microparticles based on the detected features, wherein the detected features are related to a phenotype of the cells.
US Pat. No. 10,167,247

SOLID FORMS OF TREPROSTINIL

United Therapeutics Corpo...

1. A treprostinil Form C having an X-ray powder diffractogram comprising the following peak: 6.55 °2?±0.2 °2 ?, as determined on a diffractometer using Cu-K? radiation at a wavelength of 1.54059 ?, in substantially pure form.
US Pat. No. 10,167,504

METHOD OF SEQUENCING

GENESEQUE AS, Trondheim ...

1. A method for determining a nucleotide sequence of a polynucleotide, preferably immobilised on a solid support, comprising the steps of:(i) contacting said polynucleotide with a) at least a first and second test probe each comprising a portion which may be complementary to one or more bases in said polynucleotide, and optionally, in addition, b) at least one test complementary base each of which may be complementary to a base in said polynucleotide, and covalently binding said first or second test probe to said polynucleotide when said portion of said first or second test probe is complementary to said one or more bases in said polynucleotide by ligation of said first or second test probe to said polynucleotide;
(ii) adding a first enzyme capable of removing at least part of said first test probe and at least one base of the polynucleotide being sequenced by a cleavage reaction if said first test probe bound to said polynucleotide and then sequentially adding at least a second enzyme capable of removing at least part of said second test probe if said second test probe bound to said polynucleotide, wherein each of said enzymes is different and specific for said first or second test probe;
(iii) optionally repeating steps (i) and (ii) with at least two different test probes and at least two enzymes wherein said enzymes may be the same or different to the enzymes used in step (ii) until a test probe which has a portion which is complementary to said one or more bases has bound to said polynucleotide and optionally, in addition, a test complementary base has bound to said polynucleotide, wherein only one test probe used in step (i) or step (iii) has a portion which is complementary to said one or more bases in said polynucleotide and optionally, in addition, only one test complementary base used in step (i)or step (iii) is complementary to a base in said polynucleotide, and said only one test probe binds to said polynucleotide in step (i) or step (iii) and optionally, in addition, said only one test complementary base binds to said polynucleotide in step (i) or (iii);
(iv) determining which test complementary base and/or complementary portion of the test probe bound to said one or more bases of the polynucleotide by determining whether said test complementary base and/or test probe bound to said polynucleotide during steps (i), (ii) or (iii) to thereby identify said one or more bases of the polynucleotide;
wherein each cycle of steps (i) to (iv) is performed one or more times, and in each cycle one or more bases of said sequence are identified, and wherein determining step (iv) comprises determining the presence, absence or level of a signal associated with said test probe and/or test complementary base, wherein the presence of signal is indicative of binding of said test complementary base and/or test probe and said signal is provided by a label associated with said test probe and/or test complementary base, and wherein said label is a bead and wherein the same bead is used for each test probe and/or test complementary base and said label is used to identify the one or more bases which are identified by determining which test probe is cleaved during step (ii).
US Pat. No. 10,166,736

SAG-RESISTANT SUBSTRATES AND METHODS OF PREPARING AND USING SAME

AWI Licensing LLC, Wilmi...

1. A substrate comprising:a core comprising a plurality of open cells;
a first facing layer attached to a first major side of the core by a first adhesive; and
a second facing layer attached to a second major side of the core by a second adhesive;wherein the glass transition temperature of the second adhesive is greater than the glass transition temperature of the first adhesive.
US Pat. No. 10,167,506

METHOD OF SEQUENCING NUCLEIC ACID COLONIES FORMED ON A PATTERNED SURFACE BY RE-SEEDING

Illumina, Inc., San Dieg...

1. A method of sequencing nucleic acids, the method comprising:(a) contacting a substrate having spatially distinguishable features with a plurality of nucleic acids to seed a subset of the features, thereby generating a seeded subset;
(b) amplifying the nucleic acids in the seeded subset to form nucleic acid colonies;
(c) repeating steps (a) and (b) to increase the number of seeded features, thereby generating an array of nucleic acid colonies; and
(d) sequencing the array of nucleic acid colonies.
US Pat. No. 10,167,507

METABOLIC DISEASES-RELATED ODORANT RECEPTOR GENES AND USE THEREOF

INDUSTRY-ACADEMIC COOPERA...

1. A method of screening for a candidate therapeutic composition that may be useful for treating a metabolic disease, induced by high fat diet (HFD), selected from the group consisting of dyslipidemia, fatty liver and insulin resistance syndrome, comprising:(a) contacting a sample of interest for analysis with a fat cell or muscle cell comprising the nucleotide sequence of SEQ ID NO:25; and
(b) analyzing the expression level of the nucleotide sequence in the cell,
wherein when the expression level of the nucleotide sequence of SEQ ID NO:25 is increased by the sample to he analyzed more than 2-fold from the level before treatment with the sample, then the sample is determined to be a candidate therapeutic composition that may be useful for treating the HFD induced metabolic disease.
US Pat. No. 10,166,227

BROMODOMAIN AND EXTRA-TERMINAL PROTEIN INHIBITOR COMBINATION THERAPY

CELGENE QUANTICEL RESEARC...

1. A method for treating cancer or neoplastic disease comprising administering to a human patient a therapeutically effective amount of at least one bromodomain and extra-terminal protein (BET) inhibitor, and a therapeutically effective amount of at least one chemotherapeutic agent that does not directly inhibit BET, wherein the BET inhibitor is 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one or a pharmaceutically acceptable salt thereof, and the chemotherapeutic agent is selected from the group consisting of temozolomide, romidepsin, and protein-bound paclitaxel.
US Pat. No. 10,166,740

METHODS OF FORMING METALLIC GLASS MULTILAYERS

Glassimetal Technology, I...

1. A method of forming a multilayer of metallic glass, the method comprisingproviding a base layer of the metallic glass formed of an alloy having thickness do, and initial temperature To, wherein the alloy has a critical cooling rate Rc and a time to crystallize at different temperatures upon heating the metallic glass formed of the alloy th(T);
selecting a thickness di and initial temperature Ti for a molten layer of the alloy such that:
(i) an interface temperature Ts determined by the Half-Enthalpy criterion is at least as high as the glass transition temperature Tg of the metallic glass formed of the alloy,
(ii) a characteristic cooling rate of the molten layer given by ?l?2(Ti?Ts)/4di2, where (?l=3×10?6 m2/s, is greater than Rc, and
(iii) a characteristic time scale of the base layer given by 4do2/?o?2, where ?o=3×10?6 m2/s, is shorter than th(T) at the interface temperature Ts,
depositing the molten layer with the thickness di and initial temperature Ti over the base layer forming a multilayer.
US Pat. No. 10,167,509

ANALYSIS OF NUCLEIC ACIDS

Bio-Rad Laboratories, Inc...

1. A method of identifying a plurality of target nucleic acids as being present on the same polynucleotide, the method comprising:a) separating a sample comprising a plurality of polynucleotides into a first subsample and a second subsample, wherein the polynucleotides comprise a first target nucleic acid and a second target nucleic acid;
b) contacting only the first subsample of the first and second subsamples with an agent capable of physically separating the first target nucleic acid from the second target nucleic acid if both target nucleic acids are present on the same polynucleotide;
c) following step b, separating the first subsample into a first set of partitions;
d) determining a first number of partitions in the first set of partitions that comprise at least one of the target nucleic acids, or a first number of partitions in the first set of partitions that comprise both of the target nucleic acids;
e) separating the second subsample into a second set of partitions;
f) determining a second number of partitions in the second set of partitions that comprise at least one of the target nucleic acids, or a second number of partitions in the second set of partitions that comprise both of the target nucleic acids; and
g) comparing a first value corresponding to the first number obtained in step d with a second value corresponding to the second number obtained in step f to determine whether the first target nucleic acid and the second target nucleic acid are present within the same polynucleotide;
wherein the first and second numbers both represent partitions that comprise at least one of the target nucleic acids or both represent partitions that comprise both of the target nucleic acids.
US Pat. No. 10,167,510

NUCLEIC ACIDS, METHODS AND KITS FOR THE DIAGNOSIS OF DYT6 PRIMARY TORSION DYSTONIA

Icahn School of Medicine ...

1. An isolated nucleic acid comprising the sequence of SEQ ID NO: 50 or SEQ ID NO: 51, or the complementary sequence of SEQ ID NO: 50 or 51; wherein the nucleic acid is labeled with a moiety selected from the group consisting of radioisotopes, fluorescent compounds, enzymes, and enzyme co-factors.
US Pat. No. 10,166,230

TREATMENT OF VASOMOTOR SYMPTOMS

1. A method for the treatment of vasomotor symptoms associated with menopause comprising the administration to a patient in need of such treatment a therapeutically effective amount of flibanserin, or a pharmacologically acceptable acid addition salt, hydrate or solvate, thereof, wherein said vasomotor symptoms are selected from the group consisting of night sweats, mood swings, and irritability.
US Pat. No. 10,166,742

METAL-POLYAMIDE/POLYETHYLENE-METAL LAMINATE

USINOR, Puteaux (FR) THY...

1. A metal laminate comprising between two outer metal sheets an adhesive polymer layer, characterized in that the adhesive polymer layer comprises a single polymer component, wherein the single polymer component consists of a polyamide, a copolymer of ethylene and an unsaturated carboxylic acid and/or a derivative thereof, a reactive copolymer comprising a styrene-maleic acid anhydride copolymer having a molecular weight of 1400 to 10,000, and an optional epoxy resin.
US Pat. No. 10,166,231

FREEZE DRIED DRUG NANOSUSPENSIONS

Janssen Pharmaceutica NV,...

1. A freeze-dried nanosuspension comprising4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof,
a steric stabilizer which is a solid at room temperature and which is a poloxamer, and
polyvinyl pyrrolidone;
wherein the freeze dried nanosuspension has a re-dispersibility index of at least 90% after storage for 3 months at 25° C.
US Pat. No. 10,167,512

LEUKOCYTE MICRORNAS FOR USE IN DIAGNOSIS AND TREATMENT OF ENDOMETRIOSIS

University of South Carol...

1. A method for diagnosing and/or treating endometriosis in a subject comprising:obtaining a peripheral blood sample from a subject;
isolating peripheral blood mononuclear cells from the peripheral blood sample;
purifying a total RNA sample from the peripheral blood mononuclear cells;
analyzing the total RNA sample from the subject to determine a quantity of each leukocyte microRNA of a set of leukocyte microRNAs present in the total RNA sample, wherein the set of leukocyte microRNAs comprises microRNA-1246, microRNA-1225-5p, microRNA-223, microRNA-451, microRNA-572, microRNA-143, microRNA-505, microRNA-155, microRNA-1281, microRNA-93, microRNA-181a-2, microRNA-181a, microRNA-342-5p, microRNA-21, microRNA-339-3p, microRNA-150, microRNA-17, microRNA-181b, microRNA-501-3p, microRNA-27a, microRNA-23a, microRNA-99b, microRNA-342-3p, let-7e, microRNA-769-5p, microRNA-320c, microRNA-1280, microRNA-766, and microRNA-339-5p;
comparing the quantity of each of the leukocyte microRNAs of the set to control quantities of each of the leukocyte microRNAs;
determining based upon the comparison that each of microRNA-1246, microRNA-1225-5p, microRNA-223, microRNA-451, microRNA-572, and microRNA-143, is overexpressed in the total RNA sample by a factor of about 3 or greater;
determining based upon the comparison that each of microRNA-505, microRNA-155, microRNA-1281, microRNA-93, microRNA-181a-2, microRNA-181a, microRNA-342-5p, microRNA-21, microRNA-339-3p, microRNA-150, microRNA-17, microRNA-181b, microRNA-501-3p, microRNA-27a, microRNA-23a, microRNA-99b, microRNA-342-3p, let-7e, microRNA-769-5p, microRNA-320c, microRNA-1280, microRNA-766, and microRNA-339-5p, is underexpressed in the total RNA sample by a factor of about 3 or greater; and
diagnosing the subject with endometriosis and/or administering a treatment for the endometriosis to the subject.
US Pat. No. 10,166,233

OUTPATIENT MODIFIED RAPID DETOXIFICATION FOR ADDICTION TO ALCOHOL AND DRUGS

1. A method of patient detoxification from a drug addiction on an outpatient basis, comprising administering a plurality of detoxification medicaments comprising:phenobarbital; clonidine; baclofen; ropinirole; and dicyclomine.
US Pat. No. 10,167,516

SIX-GENE BIOMARKER OF SURVIVAL AND RESPONSE TO PLATINUM BASED CHEMOTHERAPY IN SERIOUS OVARIAN CANCER PATIENTS

Wisconsin Alumni Research...

1. A method of treating a subject having ovarian cancer, the method comprising the steps of:(a) obtaining a first sample from the subject prior to treatment for ovarian cancer,
(b) measuring the expression level of AKT2, KRAS, RAC1, and CALM3 in the sample from (a),
(c) obtaining a second sample from the subject after treatment for ovarian cancer,
(d) measuring the expression level of AKT2, KRAS, RAC1, and CALM3 in the sample from (c),
(e) detecting an increased level of expression of the genes in the second sample, as compared to the level of expression of the genes in the first sample, wherein the increased level of expression is at least 1%,
(f) diagnosing the subject as in need of alternative therapy, and
(g) administering to the diagnosed subject an alternative therapy selected from the group consisting of taxane, bevacizumab, docetaxel, doxorubicin, gemcitabine, pemetrexed, tamoxifen, topotecan, and mixtures thereof.
US Pat. No. 10,167,517

MIPOL1-ETV1 GENE REARRANGEMENTS

THE REGENTS OF THE UNIVER...

1. A method for detecting a MIPOL1-ETV1 genetic rearrangement and one or more markers associated with prostate cancer in a biological sample, the method comprising:a) contacting a biological sample with:
i) a probe directly labeled with a detectable label and comprising a sequence that is complementary to a junction at which an ETV1 gene is inserted into a MIPOL1 gene; or
ii) a first probe directly labeled with a detectable label and comprising a sequence complementary to a MIPOL1 gene and a second probe directly labeled with a detectable label and comprising a sequence complementary to an ETV1 gene; or
iii) a first amplification oligonucleotide comprising a sequence complementary to a MIPOL1 gene, a second amplification oligonucleotide comprising a sequence complementary to an ETV1 gene, and a probe directly labeled with a detectable label and comprising a sequence complementary to the product produced from the first and second primers; and
b) detecting in the biological sample expression of a marker selected from the set of markers consisting of AMACR/P504S, PCA3, PCGEM1, prostein/P501S, P503S, P504S, P509S, P510S, prostase/P703P, P710P, prostate specific antigen (PSA), prostatic acid phosphatase (PAP), prostate binding protein (PBP), ABCC5(MDR5), ADAMTS1, AMACR, ANNEXINA11, ANNEXINA1, ANNEXINA4, APP, ARHB, ASNS, ATF2, C1S, C4BPA, C7, CATHEPSINB, CATHEPSINH, CAVEOLIN2, CCND2, CFLAR, CLUSTERIN, COL15A1, COL1A2, COL3A1, c-terminal binding protein, CTBP1, CTBP2, CYSTATINC, E2EPF, EDNRB, EGR1, EPHA1, ETS2, EZH2, FASN, FAT, FHL1, FIBRONECTIN1, FKBP5, FLS353, FOLH1, FOSB, FZD7, GELSOLIN, GP73, GSTM1, GSTM3, GSTM5, GSTP1, HEPSIN, HEVIN, IGFBP3, IGFBP5, IL1R1, IL1R2, ITGA1, ITGB4, ITM2C, JUN, KERATIN5, LIMK1, LUMICAN, MADH4, MAP3K10, MAPK6, MCAM, MEIS1, MEIS2, MMECD10, MOESIN, MPDZ, MTA1, MYBL2, MYLK, NBL1, NCK1, NRAS, PCM1, pim-1, PLA2G2A, PP1CB, PPP2CB, PRKCL2, PSG9, RAB2, RAB5A, RAP2, RIG, S100A11, SCYA2, SEPP1, SGK, SKI, SLUG, TACC1, TASTIN, TBXA2F, TBXA2R, TFCP2, THROMBOSPONDIN1, TIMP2, TNFS10, TNFSF10, TOP2A, TRAF4, TRAP1, UBCH10, VAV2, VIMENTIN, VINCULIN, and YWHAB.
US Pat. No. 10,167,518

METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS

Syros Pharmaceuticals, In...

1. A method of diagnosing and treating a human subject suffering from myelodysplastic syndrome (MDS), the method comprising:a. diagnosing whether the subject has a tamibarotene-sensitive form of the MDS based on a level of retinoic acid receptor alpha (RARA) mRNA previously determined to be present in a sample of diseased cells from the subject, wherein the RARA mRNA is transcribed from a RARA gene that encodes a functional retinoic acid receptor-? and specifically excludes gene fusions that comprise all or a portion of the RARA gene; and
b. administering to the subject an amount of tamibarotene effective to treat the MDS,
wherein the level of RARA mRNA is equal to or above a predetermined threshold.
US Pat. No. 10,166,238

EZH2 INHIBITORS FOR TREATING LYMPHOMA

Epizyme, Inc., Cambridge...

1. A method for treating non-Hodgkin's lymphoma (NHL) comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the NHL is primary mediastinal large B-cell lymphoma (PMBCL), and wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg to about 3200 mg daily.
US Pat. No. 10,167,519

FUSION GENES ASSOCIATED WITH PROGRESSIVE PROSTATE CANCER

1. A method of treating a subject, comprising (i) determining whether a subject is at increased risk of manifesting progressive prostate cancer comprising determining whether a prostate cancer cell of the subject contains a SLC45A2-AMACR fusion gene; and (ii) where the cell contains the SLC45A2-AMACR fusion gene so that the subject is at increased risk, performing one or more of cryotherapy, radiation therapy, chemotherapy, hormone therapy, and radical prostatectomy.
US Pat. No. 10,167,520

UNIVERSAL OR BROAD RANGE ASSAYS AND MULTI-TAG SAMPLE SPECIFIC DIAGNOSTIC PROCESS USING NON-OPTICAL SEQUENCING

1. A method for determining the identity of one or more microorganisms in a sample comprising the steps of:(a) isolating DNA or RNA from the sample;
(b) combining the DNA or RNA directly with one or more universal amplification primers, wherein the one or more universal amplification primers are specific for one or more microorganisms;
(c) amplifying the DNA, or the RNA following reverse transcription with a reverse transcriptase, wherein the universal amplification primers for the step of amplifying the DNA, or the RNA following reverse transcription with a reverse transcriptase, are SEQ ID NOS: 83 and 84, and further comprising amplifying with one or more primers specific for at least one of 23s ribosomal nucleic acids, nirS, rpoB, COX1, rbcL, LSU, 28S, fusA, ileS, lepA, leuS, pyrG, recA, recG, rplB, or SSU;
(d) contacting the amplification products of step (c) with one or more microorganism-specific detectable markers, wherein each detectable marker is a non-optical detectable marker;
(e) detecting the amplification products of step (c) with a non-optical detector; and
(f) determining both the presence or absence of the microorganism in the sample, and a copy number of the microorganism when the microorganism of the one or more target microorganisms is present.
US Pat. No. 10,167,521

METHODS AND MATERIALS FOR DETECTING CONTAMINATED FOOD PRODUCTS

Cascade Biosystems, Inc.,...

1. A kit for assessing a food product for contamination, wherein said kit comprises:(a) probe nucleic acid comprising a nucleotide sequence complementary to a sequence of a target nucleic acid present within a microorganism or virus, wherein at least a portion of said target nucleic acid is capable of hybridizing to at least a portion of said probe nucleic acid to form a double-stranded portion of nucleic acid comprising a restriction endonuclease cut site, wherein said probe nucleic acid comprises a restriction endonuclease, and
(b) signal expansion nucleic acid comprising an amplifying restriction endonuclease, a label, and a double-stranded portion of nucleic acid comprising a restriction endonuclease cut site of said restriction endonuclease of said probe nucleic acid.
US Pat. No. 10,167,522

NUCLEIC ACID PROBES AND METHODS FOR DETECTING PLASMODIUM KNOWLESI

ID-Fish Technology, Inc.,...

1. A method for detecting the presence of Plasmodium knowlesi in a sample, said method comprising the steps of:a) contacting said sample with a labeled nucleic acid probe suitable for detecting Plasmodium knowlesi in a hybridization assay, the probe consisting of a labeled nucleic acid sequence consisting of SEQ ID NO: 3 and/or SEQ ID NO: 4 and/or SEQ ID NO:5, or full-length complementary sequences thereof, under conditions that permit said probe to hybridize to Plasmodium knowlesi nucleic acid, wherein any said label is selected from one or more of radioisotopes, biotin, digoxigenin, fluorochromes, modified nucleotides and enzymes; and
b) detecting said probe bound to said Plasmodium knowlesi nucleic acid in said sample as an indication of the presence of Plasmodium knowlesi in said sample.
US Pat. No. 10,167,523

GENE IMPACTING BIOMASS FORMATION AND RECALCITRANCE AND METHODS OF USE

UT-Battelle, LLC, Oak Ri...

1. A method for increasing biomass, cellulose content or sugar release in a Populus plant, the method comprising:(i) transforming Populus plants with a recombinant binary vector comprising a DNA expression construct, wherein the DNA expression construct comprises a heterologous promoter operably linked to a first DNA segment of 100-500 nucleotides long that corresponds to at least a portion of the 3? UTR region of the IQD1 gene as set forth in SEQ ID NO: 1, a spacer segment and a second DNA segment that is fully complementary to the first DNA segment, wherein the first and second DNA segments are arranged in a 5? to 3? direction, respectively, in the DNA expression construct;
(ii) expressing said DNA construct to produce double stranded with hairpin loop RNAi inhibitory molecule in said transformed Populus plants, and wherein expression of endogenous IQD1 gene and its encoded IQD1 protein in said Populus plants is reduced;
and
(iii) selecting a transformed Populus plant from transformed Populus plants of step (ii) which expresses said RNAi inhibitory molecule and exhibits increase in biomass, cellulose content or sugar release as compared to a wild-type untransformed Populus plant species lacking said DNA expression construct.
US Pat. No. 10,167,524

VIRUS CAUSING RESPIRATORY TRACT ILLNESS IN SUSCEPTIBLE MAMMALS

Erasmus University Medica...

1. A kit for determining the presence of metapneumovirus (MPV) in a mammalian subject, the kit comprising:a DNA probe of at least 10 nucleotides that hybridizes under stringent conditions to a target polynucleotide,
wherein the target polynucleotide is a contiguous portion of a sequence encoding a polypeptide that is at least 90% identical to SEQ ID NO:8 or the complement of the sequence, and
wherein the DNA probe does not hybridize under stringent conditions to a polynucleotide from avian pneumovirus (APV).
US Pat. No. 10,166,244

TARGETING NCCA-ATP CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE

University of Maryland, B...

1. A method of treating or reducing ischemic damage in a subject comprising administering an inhibitor of an NCCa-ATP channel that is a SUR1 antagonist and/or a TRPM4 antagonist as a loading bolus dose followed by a constant infusion of a maintenance dose, wherein the bolus dose is 30-90 times the amount of the maintenance dose.
US Pat. No. 10,167,525

ASSAYS

ALERE TECHNOLOGIES GMBH, ...

1. A method, comprising:(a) providing: an amount of a reporter compound; a first binding member being configured to bind an anchor group of a capture molecule; a second binding member capable of capturing the reporter compound; an amount of a target nucleic acid capable of forming complexes with the reporter compound, the forming of complexes with the reporter compound inhibiting capturing of the reporter compound by the second binding member; and an amount of capture molecules wherein each capture molecule comprises a binding portion specific to a region of the target nucleic acid and an anchor group;
(b) forming complexes each comprising the target nucleic acid and the capture molecule;
(c) contacting the complexes with the first binding member to bind the complexes to the first binding member
(d) releasing at least a subset of the amount of target nucleic acid from the first binding member;
(e) forming complexes of a subset of the amount of reporter compound with at least a subset of the amount of target nucleic acid;
(f) capturing a remaining subset of the amount of reporter compound not in complex with the target nucleic acid on the second binding member:
(g) determining a value indicative of the amount of reporter compound captured on the second binding member; and
(h) determining a value indicative of the amount of target nucleic acid based on the value indicative of the amount of reporter compound captured on the second binding member; and
(i) wherein the value indicative of the amount of reporter compound captured on the second binding member is determined before forming complexes of the subset of the amount of reporter compound with at least the subset of the amount of target nucleic acid.
US Pat. No. 10,167,526

METHODS AND SYSTEMS FOR PREDICTING WHETHER A SUBJECT HAS A CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) LESION FROM A SUSPENSION SAMPLE OF CERVICAL CELLS

IncellDx, Inc., San Carl...

1. A method comprising:(a) receiving a cell suspension sample of cervical cells, comprising endocervical cells and ectocervical cells;
(b) fixing and permeabilizing the cervical cells of the sample;
(c) contacting the fixed and permeabilized cervical cells with a fluorescent DNA-staining reagent and fluorescent probes for HPV E6 and E7 mRNA to produce a labeled sample of cervical cells; and
(d) flow-cytometrically assaying the labeled sample of cervical cells on a flow cytometer to obtain at least:
i) a nuclear to cytoplasmic ratio of the cervical cells based on the fluorescent DNA-staining reagent,
ii) a quantification of HPV E6 and E7 mRNA expression of the cervical cells based on the fluorescent probes, and
iii) a cell cycle identification of the cervical cells based on the fluorescent DNA-staining reagent; and
(e) obtaining from the flow cytometer a determination, based on the nuclear to cytoplasmic ratio, the quantification of HPV E6 and E7 mRNA and the cell cycle identification, of whether a cell of a CIN lesion is present in the sample.
US Pat. No. 10,165,737

WARM CLOUD CATALYST, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Yougui Yan, Kunming (CN)...

1. A warm cloud catalyst, comprising following components in parts by weight:80-120 parts of a plant ash/plant powder/plant carbon powder;
0.5-5 parts of a surfactant dry powder or 15-32 parts of a surfactant solution; and
2-10 parts of a thickening agent.
US Pat. No. 10,166,505

METHOD OF TREATING GAS AND GAS TREATMENT DEVICE

CHING-JING PHOTONERGY CO....

1. A method of treating a gas, the gas comprising a nitrous oxide (N2O), the method comprising the steps of:delivering the gas to a first chamber 10, followed by supplying a first energy 11 to the first chamber 10, so as for the gas to form an excited-state ionized gas, wherein the ionized gas comprises a nitric oxide (NO) and a nitrogen atom (N);
supplying an ozone (O3) to a second chamber 20, wherein the second chamber 20 has a second energy whereby the ozone forms an excited-state oxygen atom (O);
delivering the excited-state ionized gas of the first chamber 10 and the excited-state oxygen atom of the second chamber to a third chamber 30 to allow a reaction to occur between the excited-state ionized gas and the excited-state oxygen atom such that the gas in the third chamber 30 comprises a nitrogen dioxide (NO2); and
delivering the gas of the third chamber 30 to a fourth chamber 40, wherein the fourth chamber 40 has a scrubbing system 41, and the scrubbing system 41 contains a solvent 411 for dissolving nitrogen dioxide (NO2).
US Pat. No. 10,166,251

STAT5A AND ITS FUNCTIONAL TUMOR SUPPRESSOR ANALOGS FOR TREATMENT OF MALIGNANCIES EXPRESSING NPM/ALK AND OTHER ONCOGENIC KINASES

THE TRUSTEES OF THE UNIVE...

1. A method of treating malignancies expressing an ALK+chimeric tyrosine kinase in a subject, comprising the step of administering to the subject a composition comprising a therapeutically effective amount of a small molecule chemical compound, wherein the small molecule chemical compound is a DNA Methyltransferase (DNMT) inhibitor.
US Pat. No. 10,166,252

METHOD FOR ASSESSING AND TREATING OR PREVENTING IMPAIRED PLASMA POLAR LIPID LEVELS

N.V. NUTRICIA, Zoetermee...

1. A method for treating, inhibiting, suppressing, and/or decreasing impaired plasma levels of one or more polar lipids selected from the group consisting of C16:1CE; C18:3CE; C20:4CE; PI(34:1); PI(38:2); PI(38:4); C16:0CE; C18:2CE; PA(34:3); PE(36:0); PE(38:0); aePC(36:0); aePC(38:0); aePC(38:4); aePC(40:4); lPC(18:0); lPC(18:3); lPC(20:4); PC(36:1); PC(38:0); PC(38:4); PC(40:4); DSM(18:0); aePC(32:1); aePC(32:2); aePC(34:0); PC(44:2); SM(16:0); SM(18:0); SM(22:0); SM(24:0); SM(24:1); aePC(36:5); aePC(38:5); aePC(40:5); lPC(20:5); lPC(22:5); PC(36:5); PC(38:5); PC(40:5); PI(38:5); PI(40:5); C20:5CE; C22:6CE; aePC(38:6); aePC(40:6); aePE(40:6); PC(36:6); PC(38:6); PC(40:6); PC(42:6); PI(40:6); C22:5CE; aePE(38:6); lPE(22:6); PE(38:6); PE(40:6); PI(38:6); PC(40:7); PC(40:8); PC(42:10); PC(42:7); PC(42:8); PC(42:9); PE(40:7); lPC(22:6); C19:0CE; C19:1CE; C20:0CE; C20:1CE; C20:3CE; PE(34:1); PE(34:2); PE(36:1); PE(36:2); PE(36:3); PE(36:4); PE(38:3); PE(38:4); PE(40:4); PI(36:3); PI(38:3); PS(38:4); aePC(36:1); aePC(38:1); aePC(38:2); aePC(38:3); aePC(40:2); aePC(40:3); lPC(20:3); PC(34:3); PC(36:3); PC(38:1); PC(38:2); PC(40:3); and PE(40:5) in a subject with Alzheimer's Disease (AD) or mild cognitive impairment (MCI), the method comprising administering to the subject a composition comprising:(a) at least one B vitamin selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9; and
(b) one or more of uridine and cytidine, or salts, phosphates or esters thereof.
US Pat. No. 10,167,533

WEAR-RESISTANT COPPER-BASED ALLOY, CLADDING ALLOY, CLADDING LAYER, AND VALVE SYSTEM MEMBER AND SLIDING MEMBER FOR INTERNAL COMBUSTION ENGINE

TOYOTA JIDOSHA KABUSHIKI ...

1. A wear-resistant copper-based alloy comprising:at least one selected from the group consisting of molybdenum, tungsten, and vanadium;
niobium carbide;
copper;
chromium in an amount of less than 1.0% in terms of wt %; and
a matrix and hard particles dispersed in the matrix,
wherein the hard particles comprise niobium carbide and at least one selected from the group consisting of Nb—C—Mo oxide, Nb—C—W oxide, and Nb—C—V oxide around the niobium carbide.
US Pat. No. 10,166,253

POSITIVELY CHARGED CO-POLYMERS FOR USE AS ANTIMICROBIAL AGENTS

Region Midtjylland, Vibo...

1. A method for treating, ameliorating, or preventing bacterial infections with Escherichia coli, Pseudomonas aeruginosa, or Staphylococcus aureus, said method comprising administration of an effective amount of a composition comprising a glatiramer acetate copolymer to an individual in need thereof.
US Pat. No. 10,166,254

USE OF MESENCHYMAL STEM CELL-EDUCATED MACROPHAGES TO TREAT AND PREVENT GRAFT VERSUS HOST DISEASE AND RADIATION-INDUCED INJURY

Wisconsin Alumni Research...

1. A method for treating bone marrow failure in a subject exposed to ionizing radiation, the method comprising administering to the subject a therapeutically effective amount of human IL-6 high, IL-10 high, IL-12 low, and TNF-? low mesenchymal stem cell-educated macrophages (MEMs), whereby the MEM-administered subject maintains production of white blood cells and platelets after exposure to ionizing radiation.
US Pat. No. 10,167,535

MAGNESIUM CASTING ALLOY AND METHOD OF MANUFACTURING SAME

HONDA MOTOR CO., LTD., T...

1. A magnesium casting alloy comprising Mg, Zn and Y,wherein a content of Zn is at least 1.2 atomic % but no more than 4.0 atomic %,
a content of Y is at least 1.2 atomic % but no more than 4.0 atomic %,
a composition ratio Zn/Y of Zn to Y is at least 0.9 but no more than 1.1,
an Mg purity of an Mg mother phase is at least 97.0%, and
a thermal conductivity is at least 80.0 W/m·K.
US Pat. No. 10,165,743

RHIZOBACTERIAL STRAIN AND USES FOR ENHANCING TOTAL LIPID YIELDS IN AN OILSEED CROP


wherein the Pseudomonas fluorescens strain is in association with a biologically acceptable carrier; and
wherein the Pseudomonas fluorescens strain increases total lipid yields in the oilseed crop relative to oilseed crop not exposed to the Pseudomonas fluorescens strain.
US Pat. No. 10,166,255

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY

REGENTS OF THE UNIVERSITY...

1. A method of making an engineered population of primary cells comprising:a) introducing into a population of primary cells a ribonucleic acid encoding for at least a portion of an exogenous functional T cell receptor sequence or encoding for at least a portion of an exogenous functional chimeric antigen receptor sequence;
b) reverse transcribing said ribonucleic acid, thereby producing a deoxyribonucleic acid encoding for said at least a portion of an exogenous functional T cell receptor sequence or said at least a portion of an exogenous functional chimeric antigen receptor sequence; and
c) introducing said deoxyribonucleic acid into a genomic break comprising at least a portion of a cytokine inducible SH2-containing protein (CISH) gene in a genome of at least one cell in said population of primary cells, wherein said genomic break is performed by an endonuclease and partially reduces or completely suppresses expression of said CISH gene.
US Pat. No. 10,166,256

ANTI-TUMOR T CELL IMMUNITY INDUCED BY HIGH DOSE RADIATION

The Board of Trustees of ...

1. A method for treating a cancer in a subject, the method comprising:a. activating T cells with a high dose of localized radiation at a tumor site;
b. collecting a population of cells comprising the activated T cells; and
c. administering the collected population of cells to the subject, thereby treating the cancer.
US Pat. No. 10,165,745

SOYBEAN CULTIVAR S170032

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170032, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124475.
US Pat. No. 10,166,257

PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY

IOVANCE BIOTHERAPEUTICS, ...

1. A method for treating a subject with cancer, the method comprising administering expanded tumor infiltrating lymphocytes (TILs) comprising:(a) obtaining a first population of TILs from a tumor resected from a subject by processing a tumor sample obtained from the subject into multiple tumor fragments;
(b) adding the tumor fragments into a closed system;
(c) performing a first expansion by culturing the first population of TILs in a cell culture medium comprising IL-2 to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas-permeable surface area, wherein the first expansion is performed for about 3-11 days to obtain the second population of TILs, wherein the second population of TILs is at least 50-fold greater in number than the first population of TILs, and wherein the transition from step (b) to step (c) occurs without opening the system;
(d) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 7-11 days to obtain the third population of TILs, wherein the third population of TILs is a therapeutic population of TILs which comprises an increased subpopulation of effector T cells and/or central memory T cells relative to the second population of TILs, wherein the second expansion is performed in a closed container providing a second gas-permeable surface area, and wherein the transition from step (c) to step (d) occurs without opening the system;
(e) harvesting the therapeutic population of TILs obtained from step (d), wherein the transition from step (d) to step (e) occurs without opening the system;
(f) transferring the harvested TIL population from step (e) to an infusion bag, wherein the transfer from step (e) to (f) occurs without opening the system;
(g) cryopreserving the infusion bag comprising the harvested TIL population from step (f) using a cryopreservation process; and
(h) administering a therapeutically effective dosage of the third population of TILs from the infusion bag in step (g) to the subject.
US Pat. No. 10,167,538

STEEL PIPE

1. A steel pipe, consisting of, in terms of mass %:0.06% to 0.25% of C,
0.50% or less of Si,
1.00% to 1.80% of Mn,
0.030% or less of P,
0.020% or less of S,
0.08% or less of Al,
0.008% or less of N,
0.080% or less of Nb, and
a remainder consisting of Fe and unavoidable impurities,
wherein a compressive residual stress at an outer surface measured by an X-ray method is 250 MPa or more,
a compressive residual stress at a position at a depth of 1 mm from the outer surface measured by the X-ray method is 70% or more of the compressive residual stress at the outer surface measured by the X-ray method, and
having a wall thickness of from 7 mm to 17 mm, wherein a ratio of the wall thickness to an outer diameter (wall thickness/outer diameter) is from 0.07 to 0.12.
US Pat. No. 10,165,746

SOYBEAN CULTIVAR S170033

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170033, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124476.
US Pat. No. 10,166,258

COMPOSITIONS CONTAINING PLATELET CONTENTS

Mayo Foundation for Medic...

1. A method for expanding a cell population comprising culturing a first population of cells in the presence of medium comprising a platelet lysate composition under conditions wherein said first population of cells is expanded to a second population of cells having more cells than said first population, wherein said platelet lysate composition comprises, plasma and a total protein concentration of at least about 35 mg/mL, a filtrate from a lysed platelet preparation passed through a 0.45 ?m or smaller filter and comprises greater than 200 pg of VEGF polypeptide per ml and wherein said platelet lysate composition comprises protein complexes greater than 50 kDa.
US Pat. No. 10,168,307

TUNABLE DIRECTIONAL COLOR TRANSITION COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME

Segan Industries, Inc., ...

1. An edible color change composition comprising:a food-grade ingestible component;
a color former; and
a food-grade color developer that transitions from a first color state to a second color state upon application of an applied stimulus.
US Pat. No. 10,165,747

MAIZE INBRED PH41VW

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH41VW, representative seed of the variety having been deposited under ATCC accession number PTA-124770.
US Pat. No. 10,166,259

ISOLATION OF EXOSOMES FROM COLOSTRUM POWDER AND EXOSOMAL DRUG FORMULATIONS USING THE SAME

3P Biotechnologies, Inc.,...

1. A method for isolation of purified exosomes from colostrum powder, the method comprising:a. providing a sample of either standardized bovine colostrum powder or standardized caprine colostrum powder;
b. suspending the colostrum powder in water and agitating to produce a uniform suspension;
c. subjecting the colostrum powder suspension to centrifugation at a first predetermined G-force to produce a first supernatant and collecting the first supernatant;
d. subjecting the first supernatant from step (c) to centrifugation at a second predetermined G-force to produce a second supernatant and collecting the second supernatant;
e. subjecting the second supernatant from step (d) to centrifugation at a third predetermined G-force to produce an exosomal pellet and collecting the exosomal pellet;
f. washing the exosomal pellet in de-ionized water; and,
g. suspending the exosomal pellet which contains the isolated purified exosomes in phosphate-buffered-saline (PBS), wherein the purified exosome yield is at least 8-times greater than if the exosomes were isolated from milk.
US Pat. No. 10,165,748

MAIZE INBRED PH42AN

PIONEER HI-BRED INTERNATO...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH42AN, representative seed of the variety having been deposited under ATCC accession number PTA-124771.
US Pat. No. 10,166,260

WOUND CARE PRODUCT WITH EGG SHELL MEMBRANE

Blaine Laboratories, Inc....

1. A wound care gel, comprising:a) irradiated egg shell membrane comprising protein, wherein said irradiated egg shell membrane is present in an amount of about 0.1 to about 10% by weight;
b) an antimicrobial compound in an amount of about 0.001 to about 0.1% by weight;
c) an effective amount of a tissue growth accelerator; and optionally
d) inactive ingredients;
wherein said wound care gel is obtained by:
i. mixing the irradiated eggshell membrane with an aqueous phase to provide a protein solution;
ii. partially neutralizing the protein solution by adding carbomer to provide a partially neutralized protein gel;
iii. optionally adding glycerin to the partially neutralized protein gel;
iv. adding triethanolamine to the partially neutralized protein gel of step ii) or step iii) to provide a neutralized gel;
v. adding the antimicrobial compound to the neutralized gel;
vi. adding the tissue growth accelerator; and optionally
vii. adding inactive ingredients.
US Pat. No. 10,165,749

LETTUCE VARIETY 79-577 RZ

RIJK ZWAAN ZAADTEELT EN Z...

1. A lettuce plant designated 79-577 RZ, representative seed of which having been deposited under NCIMB Accession No. 42495, wherein said plant comprises at least the following combination of traits including resistance to downy mildew (Bremia lactucae) races Bl:1-32 and Ca-I to Ca-VIII, resistance to currant-lettuce aphid (Nasonovia ribisnigri), and having medium to yellowish green colored mature leaves with a strong undulation of the apical margin.
US Pat. No. 10,166,005

MEDICAL DEVICES WITH COATINGS FOR ENHANCED ECHOGENICITY

Encapson B.V., Enschede ...

1. A medical device comprising a coating for ultrasound detection, said coating comprising microparticles that are visible with ultrasound, wherein the microparticles are solid microspheres comprising glass or silicate, and wherein the diameter of at least 60% of said microparticles on said medical device is between 22 and 45 ?m and wherein the density of said microspheres on the surface of said medical device is between 45 and 450 microspheres/mm2, and wherein at least one of the following conditions a) -e) is met;a) the diameter of at least 60% of the microspheres on the medical device is between 22 and 27 ?m and the density of the microspheres on the surface of the medical device is between 150 and 450 microspheres/mm2;
b) the diameter of at least 60% of the microspheres on the medical device is between 27 and 32 ?m and the density of the microspheres on the surface of the medical device is between 70 and 450 microspheres/mm2;
c) the diameter of at least 60% microspheres on the medical device is between 32 and 38 ?m and the density of the microspheres on the surface of the medical device is between 45 and 225 microspheres/mm2;
d) the diameter of at least 60% of the microspheres on the medical device is between 38 and 45 ?m and the density of the microspheres on the surface of the medical device is between 45 and 150 microspheres/mm2; and
e) the diameter of at least 60% of the microspheres on the medical device is between 22 and 32 ?m and the density of the microspheres on the surface of the medical device is between 150 and 450 microspheres/mm2.
US Pat. No. 10,166,262

STRAIN OF BACTERIA AND COMPOSITION COMPRISING THE SAME

1. A composition comprising a strain of Lactobacillus plantarum AMT 14 bacteria (PCM Accession No. B/00092) in an amount of 101 to 1013 of colony forming units cfu/ml, a medium, and a bulking agent.
US Pat. No. 10,165,751

CANOLA INBRED LINE G30853A

Agrigenetics, Inc., Indi...

1. A seed of canola cultivar designated G30853A, wherein a representative sample of seed of said cultivar was deposited under ATCC Accession No. PTA-122718.
US Pat. No. 10,165,752

MAIZE INBRED PH2RTF

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH2RTF, representative seed of the variety having been deposited under ATCC accession number PTA-124800.
US Pat. No. 10,166,264

BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME

CJ CHEILJEDANG CORPORATIO...

1. A method of preparing an animal feed composition, the method comprising:providing a bacteriophage composition comprising bacteriophage as an active ingredient and a additive; and
mixing the composition with an animal feed base to provide the animal feed composition,
wherein the bacteriophage has nucleic acid sequences of SEQ ID NOs: 1 to 4.
US Pat. No. 10,166,520

CATCAPSULES FOR SELF-HEALING APPLICATIONS

International Business Ma...

1. A method of making a linked microcapsule, comprising:providing a first microcapsule having a first payload agent inside the first microcapsule and a first orthogonal-functionalized unit incorporated into a wall of the first microcapsule;
providing a second microcapsule having a second payload agent inside the second microcapsule and a second orthogonal-functionalized unit incorporated into a wall of the second microcapsule; and
forming a linked microcapsule by reacting:
(a) the first microcapsule with the second microcapsule in an acyclic diene metathesis reaction,
(b) the first microcapsule with the second microcapsule in a thiol-ene click reaction,
(c) the first microcapsule with the second microcapsule in a thiol-yne click reaction,
(d) the first microcapsule with the second microcapsule in a thiol-epoxy click reaction,
(e) the first microcapsule with the second microcapsule in a Michael reaction, or
(f) a mixture of an isocyanate, the first microcapsule, and the second microcapsule.
US Pat. No. 10,166,265

PHARMACEUTICAL COMPOSITION FOR TREATING BACTERIAL AND VIRAL INFECTIONS

1. A pharmaceutical composition comprising an amount of vitamin C, zinc, vitamin A, vitamin D3, vitamin B6, garlic and Echinacea effective to treat bacterial and/or viral infections.
US Pat. No. 10,166,266

PROCESS TO ENHANCE THE BIOACTIVITY OF ASHWAGANDHA EXTRACTS

1. A method of treating stress comprising administering an enteric coated composition to a subject in need thereof, the enteric coated composition comprising extract of Withania somnifera and an enteric coating material, wherein the extract of Withania somnifera comprises by weight:at least about 3.5% withanolide glycosides,
less than about 0.1% withanolide aglycones,
less than about 0.1% alkaloids, and,
less than about 0.1% oligosaccharides,
and wherein the enteric coating material is selected from the group consisting of poly (methacrylic acid-co-methyl methacrylate), and, a combination of modified ethyl cellulose and sodium alginate.
US Pat. No. 10,167,291

PHARMACEUTICAL COMPOSITION COMPRISING A CRYSTAL FORM OF (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL) PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE

Acerta Pharma B.V., Oss ...

1. A solid pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and 95-105 mg of a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide characterized by a reflection X-ray powder diffraction pattern comprising peaks at 6.4° ±0.2° 2?, 8.6°±0.2° 2?, 10.5° ±0.2° 2?, 11.6° ±0.2° 2? and 15.7° ±0.2° 2?.
US Pat. No. 10,166,267

MULTI-COMPONENT FORMULATIONS FOR THE TREATMENT OF COGNITIVE DECLINE INCLUDING ALZHEIMER'S DISEASE

1. A multi-component formulation comprising:about 0.01% to about 5% by weight methylsulfonylmethane,
about 5% to about 99% by weight fructose 1,6-diphosphate, and
about 0.01% to about 95% by weight of at least one of an herbal component or a nutritional component comprising curcumin.
US Pat. No. 10,166,269

COMBINATIONS OF PROTEASOME INHIBITORS AND CYCLIC PEPTIDES

BIG DNA LTD, Roslin, Mid...

1. A combination comprising: (i) a proteasome inhibitor or a pharmaceutically acceptable salt thereof; and (ii) a cyclic peptide or a pharmaceutically acceptable salt thereof, wherein the cyclic peptide or a pharmaceutically acceptable salt thereof comprises an exposed Arg-Gly-Asp (RGD) moiety; and wherein the ratio of the proteasome inhibitor or a pharmaceutically acceptable salt thereof to the cyclic peptide or a pharmaceutically acceptable salt thereof ranges from 1:5000 to 1:10 w/w.
US Pat. No. 10,166,270

COMPOSITION AND METHOD FOR AFFECTING CYTOKINES AND NF-?B

Zivo Bioscience, Inc., K...

1. A method of treating inflammation in a subject in need thereof; the method comprising administering to said subject an effective amount of phyto-percolate derived from culturing microorganisms of ATCC Deposit #PTA-5863 wherein the inflammation is treated by the phyto-percolate up regulating anti-inflammatory cytokines while down regulating pro-inflammatory cytokines.
US Pat. No. 10,166,272

EFFICIENT SYSTEMIC TREATMENT OF DYSTROPHIC MUSCLE PATHOLOGIES

GENETHON, Evry (FR) ROYA...

1. A method of treating Duchenne muscular dystrophy (DMD) in a human, comprising:systemically administering by intravascular injection to a human in need thereof a gene therapy product that comprises an adeno-associated viral (AAV) vector of serotype 8 or 9 which harbors a nucleic acid sequence encoding a human ?R4-R23/?CT microdystrophin, thereby treating DMD in the human.
US Pat. No. 10,168,321

COMPOSITION COMPRISING UP-CONVERTING PHOSPHORS FOR DETECTING AN ANALYTE

Roche Diabetes Care, Inc....

1. A detector matrix for detecting at least one analyte in a sample comprising (i) at least one enzyme active in the presence of said at least one analyte and (ii) at least one indicator reagent changing at least one optical property dependent on the activity of said enzyme, wherein the indicator reagent is homogenously distributed within said detector matrix, wherein said detector matrix further comprises (iii) UV-emitting up-converting phosphor particles.
US Pat. No. 10,166,273

SYNERGISTIC TUMOR TREATMENT WITH ANTIBODIES TARGETING PD-1, PD-L1 OR CTLA4 AND INTEGRIN-BINDING-FC-FUSION PROTEIN

The Board of Trustees of ...

1. A method for inhibiting growth and/or proliferation of tumor cells in a subject comprising administering to the subject an effective amount of an integrin-binding-Fc fusion protein, wherein the integrin-binding-Fc fusion protein comprises (i) an integrin-binding polypeptide comprising an integrin-binding loop and a knottin polypeptide scaffold; and (ii) an immunoglobulin Fc domain, wherein the integrin-binding polypeptide is operably linked to the Fc domain, and an immune checkpoint blocker selected from the group consisting of an antibody or antibody fragment targeting PD-1, an antibody or antibody fragment targeting PD-L1, and an antibody or antibody fragment targeting CTLA4.
US Pat. No. 10,168,322

ELECTRONIC ANALYTE ASSAYING DEVICE

1. A diagnostic device for detecting the presence of an analyte in a fluid sample, the device comprising:a housing configured to receive a lateral flow diagnostic strip, said lateral flow diagnostic strip including:
a receiving end for receiving the fluid sample;
a terminal end opposite said receiving end; and
a capture region located between said receiving end and said terminal end; and a processor configured to, upon receiving the fluid sample:
illuminate the lateral flow diagnostic strip;
measure intensity values of light reflected from the lateral flow diagnostic strip;
obtain, during a first time period, a first series of intensity value pairs, wherein each intensity value pair of the first series of intensity value pairs comprises a measurement signal and a background signal, and wherein the measurement signal and the background signal for each intensity value pair of the first series of intensity value pairs are obtained at substantially the same time;
calculate the intensity difference between the measurement signal and the background signal for each pair of the first series of intensity value pairs to generate a first series of intensity difference values;
generate, at the end of the first time period, a fluid front detection result based at least in part on the first series of intensity difference values, wherein the fluid front detection result indicates whether at least a portion of the first series of intensity difference values correspond to a threshold for identifying a fluid front;
obtain, during a second time period, a second series of intensity value pairs, wherein each intensity value pair of the second series of intensity value pairs comprises a measurement signal and a background signal, and wherein the measurement signal and the background signal for each intensity value pair of the second series of intensity value pairs are obtained at substantially the same time;
calculate the intensity difference between the measurement signal and the background signal for each pair of the second series of intensity value pairs to generate a second series of intensity difference values; and
generate, at the end of the second time period, a message indicating that the analyte is present in the fluid sample based at least in part on:
(i) the fluid front detection result generated with the first series of intensity difference values obtained during the first time period, and
(ii) the second series of intensity difference values obtained during the second time period.
US Pat. No. 10,166,274

METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS

ALEXION PHARMACEUTICALS, ...

1. A method of treating a human patient suffering from a lysosomal acid lipase (LAL) deficiency, comprising administering to the human patient safe and effective amounts of recombinant human LAL, wherein the administration of safe and effective amounts of recombinant human LAL comprises:a) administering an initial dosage in an amount at 1 mg LAL/kg body weight one or more times, followed by
b) administering a subsequent dosage in an amount of 3 mg LAL/kg body weight one or more times.
US Pat. No. 10,168,323

COMPOSITIONS AND METHODS FOR CAPTURE OF CELLULAR TARGETS OF BIOACTIVE AGENTS

Promega Corporation, Mad...

1. A kit comprising:(a) a cell that expresses a fusion of a bioluminescent reporter and a cellular target of a small molecule bioactive agent, wherein the cellular target is located within a cell;
(b) the small molecule bioactive agent tethered by a carbamate linker to a chloroalkane capture ligand, wherein the small molecule bioactive agent tethered to a chloroalkane capture ligand is cell permeable, and wherein the small molecule bioactive agent is capable of non-covalently binding to the cellular target upon interaction thereof under intracellular conditions; and
(c) a solid surface displaying a capture protein, wherein the capture protein comprises a modified dehalogenase configured to covalently bind to the chloroalkane capture ligand upon interaction thereof.
US Pat. No. 10,165,763

ANIMAL MODELS AND THERAPEUTIC MOLECULES

Kymab Limited, Cambridge...

1. A transgenic mouse whose genome comprises a homozygous immunoglobulin heavy chain (IgH) locus comprising a human heavy chain variable region at an endogenous IgH locus, upstream of a constant (C) region, said constant region comprising an endogenous C gene segment,said human heavy chain variable region comprising a plurality of unrearranged human immunoglobulin heavy chain variable (VH) gene segments, a plurality of unrearranged human immunoglobulin heavy chain diversity (DH) gene segments and a plurality of unrearranged human immunoglobulin heavy chain joining (JH) gene segments comprising a 3?JH gene segment, wherein the human variable region gene segments in said IgH locus are operably linked to said endogenous IgH C gene segment,
said IgH locus in a 5? to 3? transcriptional orientation comprising said 3?JH gene segment, human DNA, a human/mouse DNA junction, mouse DNA, an enhancer, and said constant region;
wherein said human DNA comprises human intronic DNA downstream of and contiguous with said human JH region,
wherein said mouse DNA comprises mouse intronic DNA downstream of and contiguous with said human/mouse DNA junction and upstream of said constant region,
wherein DNA between said human/mouse DNA junction and said enhancer comprises mouse 129 strain JC intronic DNA
wherein said 3? JH gene segment is less than 2 Kb upstream of said human/mouse DNA junction,
said mouse being functional to breed to another said mouse to produce progeny having in its germline said homozygous recombinant immunoglobulin heavy chain locus,
said mouse being functional to form rearranged human VH, DH, and JH gene segments and to produce mRNA transcripts encoding immunoglobulin heavy chain polypeptide comprising a human VH region and a mouse C? region,
wherein said mouse comprises IgH mRNA transcripts comprising IgH-VDJC? transcripts encoding polypeptide comprising a human VH region and mouse C?,
wherein said IgH-VDJC? transcripts comprise transcripts encoding a human variable region comprising a CDR-H3 length of 17 amino acids and transcripts encoding a human variable region comprising a CDR-H3 length of 18 amino acids according to the Kabat numbering system,
wherein the mean frequency of the group consisting of said transcripts encoding CDR-H3 lengths of 17 and 18 amino acids present in said IgH-VDJC? transcripts of said mouse is between 5% and 10%.
US Pat. No. 10,166,275

ANTIMICROBIAL COMPOSITION COMPRISING PYROGENIC SILICA AND SERRATHIOPEPTIDASE AND USES THEREOF

Willingsford Limited., S...

1. An antimicrobial composition comprising from 90 to 99% by weight a silicious absorbent made of globules of fine hydrated pyrogenic silica and polysilicic acid (SiO2*H2O); and the remainder by weight, comprising 1 to 10% serrathiopeptidase immobilized thereon; wherein said antimicrobial composition is a dry powder.
US Pat. No. 10,166,531

CATALYST FOR SELECTIVELY CATALYTICALLY OXIDIZING HYDROGEN SULFIDE, CATALYST FOR BURNING TAIL-GAS, AND PROCESS FOR DEEPLY CATALYTICALLY OXIDIZING HYDROGEN SULFIDE TO ELEMENT SULFUR

Nan Yang, Zibo, Shandong...

1. A catalyst for selectively catalytically oxidizing hydrogen sulfide, comprising components of a mass percent of: 13-34% of iron trioxide, 60-72% of anatase titanium dioxide and a balance which are auxiliary agents.
US Pat. No. 10,166,276

COMPOSITIONS AND METHODS FOR TREATMENT OF NON-HODGKINS LYMPHOMA

The Trustees of the Unive...

1. A method of inducing an immune response against a B cell lymphoma in a subject, comprising administering a pharmaceutical composition comprising a fusion polypeptide comprising a fragment of a listeriolysin O (LLO) protein and an antigen, wherein said fragment of an LLO protein is chemically conjugated to said antigen, wherein said antigen is a fragment of a B cell receptor (BCR) comprising the idiotype of said BCR, and wherein said fragment of an LLO protein is an N-terminal fragment comprising the amino acid sequence set forth in SEQ ID NO: 25 or an N-terminal LLO-detox fragment comprising the amino acid sequence set forth in SEQ ID NO: 41.
US Pat. No. 10,167,301

PROCESS FOR THE PREPARATION OF BIS(CHLOROMETHYL)DICHLOROSILANE AND BIS(CHLOROMETHYL)(ARYL)CHLOROSILANE

Dow Global Technologies L...

1. A process for the preparation of bis(chloromethyl)dichlorosilane comprising reacting bis(chloromethyl)diarylsilane and one or more chloride compounds in the presence of one or more Lewis acids in an inert solvent and under an inert atmosphere.
US Pat. No. 10,168,325

NON-SPECIFIC REACTION INHIBITOR

LSI MEDIENCE CORPORATION,...

1. A method for inhibiting a non-specific reaction in an immunological measurement, said method comprising:preparing a sample containing an antigen to be measured;
preparing a solution containing a polymer-modified fragment of an antibody specific to a non-specific reaction factor, wherein the polymer is selected from the group consisting of polyethylene glycol, dextran, bovine serum albumin, and polyglutamic acid, the fragment of the antibody is Fab?, and the non-specific reaction factor is selected from the group consisting of IgM, IgG, IgA, IgE, and IgD;
mixing the solution with the sample to react the polymer-modified fragment with the non-specific reaction factor, before an antibody specific to the antigen is reacted with the antigen, and adding the antibody specific to the antigen to the mixture; and
inhibiting a non-specific reaction caused by the non-specific reaction factor.
US Pat. No. 10,170,121

SPEECH RECOGNITION SYSTEM AND METHOD FOR OPERATING A SPEECH RECOGNITION SYSTEM WITH A MOBILE UNIT AND AN EXTERNAL SERVER

Volkswagen AG, (DE)

1. A transportation vehicle user interface voice recognition system comprising:a mobile unit provided on a transportation vehicle; and
an external server, wherein the mobile unit and the external server are in communication with each other, wherein the mobile unit comprises;
a memory that stores voice model data that comprise at least one expression set with expressions for controlling transportation vehicle functionality using voice input of a user;
a voice recognition unit configured to use the voice model data as a basis for producing a recognized text for captured voice input data generated based on the voice input of the user, wherein the recognized text is analyzed to determine how to control the transportation vehicle functionality; and
a data interface that at least intermittently sets up a data-oriented connection to a data interface of the external server,
wherein the external server comprises:
a database with event data having associated time data and expressions for controlling transportation vehicle functionality, the external server being configured to produce update data for the voice model data stored in the memory of the mobile unit by comparing the time data associated with the event data with a current time,
wherein the update data for the voice model data comprises at least expressions associated with the event data in the external server database,
wherein the external server is further configured to transmit the update data from the external server to the data interface of the mobile unit,
wherein the transmitted expressions are added to the stored at least one expression set based on the update data and a subset of expressions of the at least one expression set stored in the memory are erased from the memory based on the update data, and
wherein the event data of the database further have associated geographical position data, wherein the voice recognition system further includes a position finding unit configured to determine a current position of the mobile unit, wherein position finding unit is configured to transmit the current mobile unit's position to the external server, and wherein the update data are further produced by the external server by comparing the geographical position data associated with the event data with the mobile unit's position.
US Pat. No. 10,166,277

VAULT IMMUNOTHERAPY

The Regents of the Univer...

1. A method for stimulating presentation of a tumor antigen to the MHC Class I pathway in dendritic cells in a subject, comprising administering to the subject an effective amount of a vault complex comprising a major vault protein (MVP) and the tumor antigen or an antigenic fragment thereof encapsulated therein.
US Pat. No. 10,168,326

INTERFERENCE-SUPPRESSED IMMUNOASSAY TO DETECT ANTI-DRUG ANTIBODIES IN SERUM SAMPLES

F. HOFFMANN-LA ROCHE INC....

1. An interference-suppressed immunoassay for the detection of anti-drug antibodies against a drug antibody for the treatment of rheumatoid arthritis, juvenile arthritis, or osteoarthritis, said method comprising:(a) incubating a sample from a rheumatoid arthritis, juvenile arthritis, or osteoarthritis patient treated with said drug antibody simultaneously with a mixture comprising 0.5 ?g/ml to 10 ?g/ml of a 1:1 conjugate of said drug antibody to a first member of a binding pair via a single lysine residue as a capture drug antibody and 0.5 ?g/ml to 10 ?g/ml of a 1:1 conjugate of said drug antibody to a detectable label via a single lysine residue as a tracer drug antibody for 0.5 to 24 hours to generate a capture drug antibody/anti-drug antibody/tracer drug antibody complex, wherein the sample comprises 1% to 20% serum and is supplemented with oligomeric human IgG prior to the incubation to a final concentration of 10 ?g/ml to 1000 ?g/ml,
(b) immobilizing the capture drug antibody/anti-drug antibody/tracer drug antibody complex formed in step (a) on a solid phase by covalently or non-covalently conjugating said first member of a binding pair to a second member of a binding pair on the solid phase,
(c) incubating the immobilized complex with an antibody against the detectable label of the tracer drug antibody, conjugated to a second detectable label, and
(d) detecting the anti-drug antibodies against said drug antibody via a signal of the detectable label of the antibody of step (c), and
wherein the drug antibody is an anti-inflammatory antibody.
US Pat. No. 10,166,534

METHOD FOR REDUCTION OF ORGANIC MOLECULES

RHEINISCH-WESTFALISCHE TE...

10. The method according to claim 7, wherein the sulfonic acid is selected from the group consisting of methanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, p-bromobenzosulfonic acid, p-nitrobenzosulfonic acid, sulfuric acid, hydrochloric acid, hydrofluoric acid, trifluoroacetic acid, perchloric acid, bis(trifluoromethane)sulfonimide and mixtures thereof.
US Pat. No. 10,166,279

VACCINE

The Administrators of the...

1. A mutant of an E. coli heat-stable toxin (ST) having the following wild-type sequence:NSSNYCCELCCNPACTGCY (SEQ ID NO: 1)
wherein the mutant has one or two mutations, and wherein the mutant comprises a mutation selected from the group consisting of: A14T and N12T.
US Pat. No. 10,168,329

N-ACETYL-D-GLUCOSAMINE FOR ENHANCED SPECIFICITY OF STREP A IMMUNOASSAY

Quidel Corporation, San ...

1. A device, comprising: a matrix comprising (i) a sample receiving zone, (ii) a labeling zone containing a labeled antibody with specific binding to Group A streptococcus antigen, to form a labeled antibody-bound antigen, and (iii) a capture zone having means for specifically binding the antibody-bound antigen thereon, wherein the sample receiving zone, the labeling zone and the capture zone are arranged on the matrix in a liquid flow path, and wherein at least one of the sample receiving zone and the labeling zone comprises N-acetyl-D-glucosamine (NAG) monomer which reduces the rate of false positives for providing accurate detection of Group A streptococcus infection.
US Pat. No. 10,166,281

METHOD AND COMPOSITION FOR MODULATING IMMUNE RESPONSE

VLP Therapeutics, LLC, W...

1. A method for modulating an immune response against a cancer, wherein said method comprises administering, to a subject with a cancer, an effective amount of a composition comprising an alphavirus virus like particle, wherein said alphavirus virus like particle does not contain a heterologous antigen.
US Pat. No. 10,167,306

CRYSTALLINE FORM OF 1-(BETA-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE AND PREPARATION METHOD THEREOF

SHANGHAI DESANO PHARMACEU...

1. A crystalline form W of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, wherein the crystalline form W has an X-ray powder diffraction pattern substantially as shown in FIG. 1.
US Pat. No. 10,168,330

MARKER SYSTEM, IN PARTICULAR FOR BACULOVIRUS-EXPRESSED SUBUNIT ANTIGENS

Boehringer Ingelheim Vetm...

1. A method of differentiating a non-vaccinated mammal or bird from a mammal or bird which has received an immunogenic composition comprising the steps of:a. obtaining a biological sample from a mammal or bird;
b. contacting antibodies of the biological sample with a capture reagent, wherein the capture reagent specifically binds antibodies specific for a rhabdovirus antigen and is selected from:
i. a polypeptide comprising a sequence having at least 95% sequence identity with any one of SEQ ID NOs: 1 to 8;
ii. a RNA virus which comprises a polypeptide comprising an amino acid sequence having at least 95% sequence identity with the sequence of SEQ ID NO: 1 and/or SEQ ID NO: 7; and
iii. a synthetic polypeptide having a sequence selected from the sequences consisting of 5 to 11 consecutive amino residues of SEQ ID NO: 1 or SEQ ID NO: 7; and
c. detecting for the presence of capture reagent-antibody complexes,
wherein the presence of capture reagent-antibody complexes indicates that said mammal or bird has received said immunogenic composition, and thus differentiates a vaccinated mammal or bird from a non-vaccinated mammal or bird.
US Pat. No. 10,166,282

IMMORTALIZED PORCINE ALVEOLAR MACROPHAGE

Intervet Inc., Madison, ...

1. A method of isolating progeny Porcine Respiratory and Reproductive Virus (PRRSV) from an immortalized porcine alveolar macrophage (PAM) cell, wherein said PAM cell is susceptible to PRRSV, expresses an SV40 T antigen, and does not comprise retroviral Long Terminal Repeat DNA capable of retroviral gene expression; wherein said method comprises the steps of:a) obtaining an aliquot of PAM cells;
b) transfecting said aliquot of PAM cells with a DNA molecule comprising transposons and comprising a gene encoding the SV40 T antigen under the control of a suitable promoter;
c) culturing the transfected PAM cells for at least 5 cell cycles;wherein immortalized PAM cells are obtained;d) selecting immortalized PAM cells;
e) further culturing the immortalized PAM cells;
f) contacting the immortalized PAM cells with a PRRSV;
g) allowing the PRRSV to replicate and form progeny PRRSV; and
h) isolating the progeny PRRSV.
US Pat. No. 10,166,538

ACTIVATION AND REGENERATION OF FLUORINATION CATALYSTS, AND FLUORINATION PROCESS

Arkema Inc., King of Pru...

1. A method of reactivating a spent or depleted chromium oxide-based fluorination catalyst, comprising contacting the spent or depleted chromium oxide-based fluorination catalyst with an agent that is a source of reactive fluorine selected from the group consisting of interhalogens, hypofluorites, fluorinated peroxides, OF2, O2F2, N2F2, N2F4, SOF4, SOF2, XeF2, XeF4, XeF6, KrF2, FNO, FNO2, FClO3, and mixtures thereof.
US Pat. No. 10,167,307

PROCESS FOR EXTRACTION OF SAPONINS FROM AGRICULTURAL PRODUCTS

Minn-Dak Farmers Cooperat...

1. A process for extracting saponin from agricultural feedstocks, comprising:preparing an agricultural feedstock for saponin extraction from the agricultural feedstock;
introducing the prepared agricultural feedstock and water into a tank to form a feedstock water solution;
adjusting the pH of the feedstock water solution to extract a saponin solution in an extraction liquid form;
clarifying the extraction liquid form to remove any insoluble suspended solids from the saponin solution;
filtering the saponin solution with a microfiltration member to separate a clean filtrate and a concentrated saponin solution, such that a saponin level within the concentrated saponin solution is concentrated by about 2 to about 10 times as compared to the saponin level in the saponin solution;
adjusting a pH of the concentrated saponin solution through the addition of an acid such that the pH of an acidified concentrated saponin solution is within a pH range from about 2 to about 7;
centrifuging the acidified concentrated saponin solution to separate suspended saponin solids from the acidified concentrated saponin solution thereby forming a suspended solid stream and a saponin-rich centrate; and
drying the suspended solid stream to form a purified saponin product.
US Pat. No. 10,168,331

DIAGNOSIS OF UROTHELIAL CANCER

RANDOX LABORATORIES LTD.,...

1. A method, comprising:measuring the level of each biomarker of a panel of protein biomarkers in a urine sample obtained from a subject having a history of smoking, wherein the panel of biomarkers consists of:
urinary epidermal growth factor (EGF), urinary IL6, urinary vascular endothelial growth factor (VEGF) and urinary cytokeratin 18 (CK18).
US Pat. No. 10,166,283

NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN

1. A nucleic acid sequence comprising or coding fora) a coding region, encoding at least one peptide, wherein said peptide is not a histone peptide;
b) at least one histone stem-loop; and
c) a poly(A) sequence or polyadenylation signal;
wherein said peptide comprises a pathogen antigen or an antigenic fragment thereof, wherein the antigen is an antigen from a pathogen associated with infectious disease.
US Pat. No. 10,168,332

METHOD FOR PREDICTING PROGNOSIS OF ACUTE MYELOID LEUKEMIA RELAPSE

The Catholic University o...

1. A method for selecting treatment for an acute myeliod leukemia (AML) patient, comprising:i) obtaining a bone marrow sample from said leukemia patient following complete remission from acute myeloid leukemia;
ii) assaying cells of said bone marrow sample to determine levels of stromal cells selected from the group consisting of primitive mesenchymal stromal cells, differentiated mesenchymal stromal cells and osteoblastic cells;
iii) referring patients having increased levels of primitive mesenchymal stromal cells in said sample compared to levels of primitive mesenchymal stromal cells of a healthy, leukemia-free individual for anti-AML treatment, and/or
iv) referring patients having increased levels of differentiated mesenchymal stromal cells and/or osteoblastic cells in said sample compared to levels of differentiated mesenchymal stromal cells and/or osteoblastic cells of a healthy, leukemia-free individual for anti-AML treatment.
US Pat. No. 10,165,772

METHODS AND COMPOUNDS FOR INCREASING RED BLOOD CELL SURVIVAL

1. A blood or blood product storage kit comprising (a) a bag for ex vivo blood or blood product storage and (b) a conservation solution comprising from 10 ?M to 200 ?M of serotonin.
US Pat. No. 10,168,077

SELF-HEATING THERMAL INTERFACE MATERIAL

International Business Ma...

1. A self-heating thermal interface material (TIM), the self-heating TIM comprising:a TIM; andat least one heat producing component dispersed within the TIM, wherein the at least one heat producing component further comprises:at least one first microcapsule, the at least one first microcapsule having an outer shell, the outer shell forming a boundary between the TIM and contents of the at least one first microcapsule, the outer shell configured to sustain application of a compressive force without rupturing;
at least one first reactant and an at least one second reactant contained within the outer shell; and
at least one isolating structure within the outer shell, the at least one isolating structure preventing the at least one first reactant and the at least one second reactant from coming into contact when the compressive force is not applied, the at least one isolating structure configured to rupture when the compressive force is applied, the rupturing causing the at least one first reactant and the at least one second reactant to come into contact, the contact producing an exothermic reaction, the heat from the exothermic reaction transferring to the TIM.
US Pat. No. 10,166,285

RECOMBINANT VIRUS WITH DIMINISHED LATENCY AND METHODS OF USING SAME

1. A recombinant virus comprising all or a portion of a herpes virus genome, wherein a latency gene or its promoter is altered or modified so that the latency gene is overexpressed or has reduced expression, wherein the latency gene is a gene that corresponds to VZV ORF29 gene and encodes a major DNA binding protein, and wherein the virus has an impaired ability to establish latency and at least one of:the promoter is a heterologous promoter;
the latency gene is at a different location in the genome relative to its native location; or
a combination thereof.
US Pat. No. 10,168,334

IDENTIFICATION OF CANCER PROTEIN BIOMARKERS USING PROTEOMIC TECHNIQUES

Yale University, New Hav...

1. A method comprising:(a) measuring the expression level of proteins that consist essentially of prolactin, osteopontin (OPN), leptin, and at least one additional protein in a sample from a female subject, wherein the at least one additional protein is selected from macrophage migration inhibitory factor (MIF), insulin-like growth factor (IGF-II), 6Ckine, angiotensin converting enzyme (ACE), brain-derived neurotrophic factor (BDNF), E-Selectin, epidermal growth factor (EGF), eotaxin-2 (Eot-2), epidermal growth factor receptor 1 (ErbB 1), follistatin, hemofiltrate CC chemokine 4 (HCC4), herpes virus entry mediator (HVEM), insulin-like growth factor binding protein 2 (IGFBP-2), interleukin-17 (IL-17), interleukin 1 soluble receptor II (IL-1sRII), interleukin 2 soluble receptor alpha (IL-2 sR?), macrophage colony stimulating factor receptor (M-CSF R), macrophage inflammatory protein 1alpha (MIP-1?), macrophage inflammatory protein 3 beta (MIP3?), matrix Metalloproteinase-8(MMP-8), matrix metalloproteinase 7 (MMP-7), myeloid progenitor inhibitory factor 1 (MPIF-1), pulmonary and activation-regulated chemokine (PARC), platelet-derived growth factor receptor beta (PDGF R ?), protein C, tumor necrosis factor receptor 1 (TNF-RI), tumor necrosis factor alpha (TNF-?), soluble Vascular Adhesion Protein-1(sVAP-1), vascular endothelial growth factor receptor 2 (VEGF R2), VEGF receptor 3 (VEGF R3), human stratum corneum chymotryptic enzyme (HSCCE), kallikrein 4, kallikrein 5, kallikrein 6 (protease M), kallikrein 8, kallikrein 9, kallikrein 10, cancer antigen 125 (CA 125), CA15-3, CA19-9, OVX1, lysophosphatidic acid (LPA), carcinoembryonic antigen (CEA), macrophage colony-stimulating factor (M-CSF), prostasin, CA54-61, CA72, HMFG2, interleukin-6 (IL-6), interleukin-10 (IL-10), LSA, NB70K, PLAP, TAG72, TPA, UGTF, WAP four-disulfide core domain 2 (HE4), matrix metalloprotease 2, tetranectin, inhibin, mesothelin, MUC1, vascular endothelial growth factor (VEGF), NOTCH3, E2F transcription factor 3 (E2F3), GTPase activating protein (RACGAP1), hemotological and neurological expressed 1 (HN1), apolipoprotein A1, laminin, claudin 3 (CLDN3), claudin 4, tumor-associated calcium signal transducer 1 (TROP-1/Ep-CAM), tumor-associated calcium signal transducer 2 (TROP-2), ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, matriptase (TADG-15), stratifin, transforming growth factor-beta receptor III (TGF-?-RIII), platelet-derived growth factor receptor alpha, SEMACAP3, ras homology gene family member I (ARHI), thrombospondin 2, disabled-2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2), and haptoglobin-alpha subunit in the sample from the subject;
(b) comparing the expression level of each of the measured proteins to a reference sample for each of the measured proteins; and
(c) determining if there is a significant difference in the expression level of each of the measured proteins in the sample as compared to the reference sample.
US Pat. No. 10,165,774

DEFOAMER USEFUL IN A PERACID COMPOSITION WITH ANIONIC SURFACTANTS

Ecolab USA Inc., Saint P...

1. A low-foaming equilibrium peracid composition comprising:a C1-C22 peroxycarboxylic acid;
a C1-C22 carboxylic acid;
hydrogen peroxide;
a mineral acid;
an anionic surfactant; and
from about 0.6 wt-% to about 0.75 wt-% of a metal salt defoaming agent, wherein the defoaming agent is aluminum sulfate;
wherein the composition has a use solution pH below about 4;
wherein the composition is provided as a concentrate, and wherein the composition is subsequently diluted at a ratio of between about 1:100 and about 1:5,000.
US Pat. No. 10,166,286

MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAME

The Board of Trustees of ...

1. A method of treating an autoimmune disease or inflammatory disease in a human subject in need thereof, the method comprising administering to the subject a mixed allergen composition comprising:2 to 20 different flours or powders, wherein at least one flour or powder is a nut flour selected from the group consisting of peanut, almond, walnut, cashew, hazelnut, pecan, and pistachio, at least one flour or powder is an animal powder selected from the group consisting of shrimp, cod, and salmon, and the mixed allergen composition comprises equal parts by protein weight of each flour or powder; and optionally
a vitamin selected from the group consisting of vitamin D and vitamin C;
wherein the composition is administered to the subject at least weekly or at least every other week.
US Pat. No. 10,167,312

METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS

RHYTHM PHARMACEUTICALS, I...

1. A method for treating obesity or a metabolic syndrome in a subject in need thereof, wherein the method comprises administering to said subject an effective amount of Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 (SEQ ID NO: 140) or a pharmaceutically acceptable salt thereof, wherein the subject is a heterozygous carrier of an MC4R mutation.
US Pat. No. 10,166,288

VACCINES HAVING AN ANTIGEN AND INTERLEUKIN-21 AS AN ADJUVANT

THE TRUSTEES OF THE UNIVE...

1. A vaccine comprisinga.) at least one selected from the group consisting of an antigen and a nucleic acid molecule encoding an antigen; and
b.) a nucleic acid molecule comprising a nucleotide sequence encoding IL-21, wherein the nucleotide sequence comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO: 3 and a nucleotide sequence that is 95% identical or greater to SEQ ID NO: 3.
US Pat. No. 10,168,337

METHOD AND BIOMARKERS FOR THE DETECTION OF DENGUE HEMORRHAGIC FEVER

THE BOARD OF REGENTS OF T...

1. A method for treating a subject having a dengue virus infection comprising:(a) measuring levels of (i) high molecular weight albumin, (ii) complement factor D and (iii) complement factor H; and determining a ratio of complement factor D to complement factor H (FactorD/FactorH) in a serum sample from the subject;
(b) measuring levels of IL2, desmoplakin, or IL2 and desmoplakin in a serum sample from the subject;
(c) determining with an accuracy of at least 90% by multivariate adaptive regression splines (MARS) classifier if the subject is at risk of developing dengue hemorrhagic fever (DHF) based on (i) the levels of high molecular weight albumin, (ii) the FactorD / FactorH ratio, and (iii) the levels of desmoplakin, or the levels of desmoplakin and IL2; and
(d) treating the subject with intensive supportive care if the subject is determined to be at risk of developing DHF.
US Pat. No. 10,166,289

COMPOSITIONS INCLUDING BETA-GLUCANS AND METHOD OF USE

Biothera, Inc., Eagan, M...

1. A method comprising:administering to a subject a first composition that comprises a yeast-derived soluble ?-glucan; and
administering to the subject a second composition that comprises a TLR agonist component, which is administered subsequent to the first composition;
wherein each of the first composition and second composition is in an amount that, in combination with the other, is effective to increase the subject's immune response to an antigen.
US Pat. No. 10,167,570

N-TYPE SIC SINGLE CRYSTAL AND METHOD FOR ITS PRODUCTION

TOYOTA JIDOSHA KABUSHIKI ...

1. A n-type SiC single crystal, which is grown on a SiC seed crystal substrate, the n-type SiC single crystal comprising germanium and nitrogen, wherein the density ratio of the germanium and the nitrogen [Ge/N] satisfies the relationship 0.24?[Ge/N]?0.83,the nitrogen density [N] satisfies the relationship 1.00×1019/cm3?[N]?1.00×1020/cm3,
the germanium density [Ge] satisfies the relationship 1.70×1018/cm3<[Ge]<1.60×1020/cm3, and the n-type SiC single crystal has a resistivity of 10 m?·cm or lower, and the same threading dislocation density level as the seed crystal substrate.
US Pat. No. 10,168,338

METHODS OF IDENTIFYING MODULATORS OF SESTRIN-GATOR-2 INTERACTION FOR MODULATING MTORC1 ACTIVITY

Whitehead Institute for B...

1. A method of identifying a test compound as an activator of mTORC1 activity comprising the steps of:a) providing a mixture comprising:
(i) a first polypeptide comprising the amino acid sequence of Sestrin1 (SEQ ID NO:1), Sestrin2 (SEQ ID NO:2), Sestrin3 (SEQ ID NO:3), or a polypeptide having at least 90% sequence identity to any one of SEQ ID NOs:1-3 that retains the ability to bind GATOR2; and
(ii) a second polypeptide or protein complex comprising the amino acid sequence of a GATOR2 complex (SEQ ID NOs:4-8), or a polypeptide or protein complex having at least 90% sequence identity to SEQ ID NOs:4-8 that retains the ability to bind to at least one of Sestrin1, Sestrin2 or Sestrin3,under conditions that allow the first polypeptide to associate with the second polypeptide or protein complex;b) incubating the mixture of a) with the test compound;
c) determining whether the amount of the first polypeptide associated with the second polypeptide or protein complex is altered in the presence of the test compound as compared to either the absence of the test compound or the presence of a negative control, wherein if the amount of association is decreased the test compound is identified as an activator of mTORC1 activity.
US Pat. No. 10,165,778

METHOD FOR CONTROLLING PESTS IN SOYBEAN

BASF SE, Ludwigshafen (D...

1. A method for controlling pests from the family of Pentatomidae and/or Thripidae, comprising contacting the pests, their food supply, habitat and/or breeding ground with one or more components of the ginkgo tree selected from the group consisting of bilobalide, ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J and ginkgolide M.
US Pat. No. 10,166,290

INTRALESIONAL (INTRATUMORAL) DINITROCHLOROBENZENE AND ASSOCIATED COMPOUNDS COADMINISTERED WITH CHECKPOINT INHIBITORS FOR CANCER TREATMENT INCLUDING TREATMENT OF METASTATIC CUTANEOUS CANCERS

1. A method of treating a primary or recurrent cancerous nodule or nodules in a subject comprising administering an intralesional injection of compounds including dinitrohalogenated benzene in association with the use of previous, subsequent, or simultaneous administration of a checkpoint inhibitor selected from the group consisting of ipilimumab, pembrolizumab, nivolumab and tremelimumab.
US Pat. No. 10,168,339

MARKER PEPTIDE FOR DETERMINING RISK OF DEVELOPING METABOLIC SYNDROME, AND USE THEREOF

LION CORPORATION, Tokyo ...

1. A method of detecting a level of at least one peptide with a minimum length of 10 amino acids of amino acids 23 to 79 of SEQ ID NO:1, the method comprisingmeasuring the level of the at least one peptide in a sample obtained from a subject,
wherein the level of the at least one peptide is measured by mass spectrometry, an immunoassay using an antibody or an aptamer which binds to the at least one peptide or an immunoassay using the microarray in which an antibody or an aptamer which binds to the at least one peptide has been is immobilized to a carrier.
US Pat. No. 10,166,803

RECORDING MEDIUM

Canon Kabushiki Kaisha, ...

1. A recording medium comprising:a substrate; and
an ink-receiving layer provided on the substrate,
wherein the ink-receiving layer comprises a silica particle and a water-insoluble resin, and
wherein the silica particle satisfies the following expressions 1 and 2 when an average pore radius thereof determined by the BJH method is taken as r (nm), and an oil absorption thereof measured by the linseed oil droplet method is taken as V (ml/100 g):
r?5.0 (nm); and  expression 1:
V/r?80 ((ml/100 g)/nm).  expression 2:
US Pat. No. 10,168,340

METHODS FOR THE DIAGNOSIS OF AMYOTROPHIC LATERAL SCLEROSIS

The Translational Genomic...

1. A method of determining whether a subject is likely to have amyotrophic lateral sclerosis, the method comprising the steps of:receiving a muscle sample from the subject;
adding a reagent capable of binding to a marker selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 6 to a mixture comprising the muscle sample;
subjecting the mixture to conditions that allow detection of binding of the reagent to the marker;
assessing an expression level of the marker in the muscle sample and a control sample, wherein assessing the expression level comprises determining a level of binding of the reagent to the marker in the muscle sample and determining a level of binding to the marker in the control sample; and
determining that the subject has amyotrophic lateral sclerosis when the expression level of the marker in the muscle sample is greater than the expression level of the marker in the control sample.
US Pat. No. 10,165,780

METHODS AND COMPOSITIONS FOR TREATING POLLUTION

Aqua Dynamic Solutions, L...

1. A water treatment puck comprising:a. an oxidative alkali in a concentration from 30 to 50 percent by weight of the puck;
b. a clarifying agent comprising a dry powdered form of an activated botanical protein obtained from drumstick tree seed material (genus Moringa) in a concentration from 5 to 20 percent by weight of the puck; and
c. a dry powdered form of a Ricinus seed extract in a concentration from 0.5 to 20 percent by weight of the puck,
wherein the puck is a compressed homogenous mixture.